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Myocarditis is a rare but potentially devastating inflammatory disease of the heart. Severity can vary widely 
from asymptomatic to fulminant disease and sudden death. Up to 30% of myocarditis patients go on to 
develop inflammatory dilated cardiomyopathy (DCMi), which is a major cause of heart failure in children 
and young adults. Patients with eosinophilia frequently develop cardiomyopathy, suggesting a pathogenic 
role for eosinophils in the heart. We used the experimental autoimmune myocarditis (EAM) model in 
different genetically modified mice to determine the role of eosinophils in myocarditis and DCMi. Using 
adoptive transfer experiments and CCR3-/- mice, we found that the eotaxin-CCR3 pathway was required for 
eosinophil trafficking to the heart in mice with eosinophilic myocarditis. We identified cardiac fibroblasts 
as the source of eotaxin-1 and infiltrating macrophages as the source of eotaxin-2. Eotaxins were also 
increased in patients with eosinophilic myocarditis compared to chronic lymphocytic myocarditis and 
eotaxin expression was positively correlated with the number of heart-infiltrating eosinophils. We then 
showed that eosinophils contribute to myocarditis pathology. Eosinophils were dispensable for myocarditis 
induction but required for progression to DCMi. Eosinophil-deficient ΔdblGATA1 mice, in contrast to WT 
mice, showed no signs of heart failure by echocardiography. Induction of EAM in hypereosinophilic IL-5Tg 
mice resulted in eosinophilic myocarditis with severe atrial inflammation, which progressed to severe DCMi. 
This was not a direct effect of IL-5 as IL-5TgΔdblGATA1 mice were protected from DCMi while IL-5-/- mice 
exhibited DCMi comparable to WT mice. Eosinophils drove progression to DCMi through their production 
of IL-4. Our experiments showed eosinophils were the major IL-4 expressing cell type in the heart during 
EAM, IL-4-/- mice were protected from DCMi like ΔdblGATA1 mice, and eosinophil-specific IL-4 deletion 
resulted in improved heart function. In conclusion, eosinophils drive progression of myocarditis to DCMi, 
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Chapter 1: Introduction 
Myocarditis 
An older, widely-used definition of myocarditis are the so-called Dallas criteria1. This histopathological 
categorization requires an inflammatory infiltrate of the heart muscle with associated myocyte damage or 
necrosis in the absence of an ischemic event. In 1995, myocarditis was defined as “an inflammatory disease 
of the myocardium, diagnosed by established histological, immunological, and immunohistochemical 
criteria” by the World Health Organization / International Society and Federation of Cardiology (ISFC). 
Inflammatory cardiomyopathy is myocarditis with an associated cardiac dysfunction. These definitions have 
more recently been reiterated and refined by the European Society of Cardiology (ESC)2. Histological criteria 
were defined as “histological evidence of inflammatory infiltrates within the myocardium associated with 
myocyte degeneration and necrosis of non-ischaemic origin” in accordance with the Dallas criteria1. The 
immunohistochemical criteria for an abnormal inflammatory infiltrate were defined as “≥ 14 
leucocytes/mm2 including up to 4 monocytes/mm2 with the presence of CD3 positive T-lymphocytes ≥ 7 
cells/mm2”.  
These definitions require an endomyocardial biopsy (or postmortem autopsy) and histological analysis of 
tissues to determine the presence of infiltrating immune cells. Moreover, special subtypes of myocarditis 
with unique prognoses and treatment can often not be diagnosed by noninvasive testing3. The complication 
rate is low and, most importantly, the infection status, which determines treatment strategy, can only be 
determined with an endomyocardial biopsy2.  However, endomyocardial biopsies are not universally 
employed for the diagnosis of myocarditis. Critics argue that the sensitivity is low and that complications 
and costs are not justified4. A common statement by the American Heart Association, American College of 
Cardiology and the European Society of Cardiology delineates specific clinical circumstances that justify 
endomyocardial biopsies3. These include new-onset heart failure with hemodynamic compromise, relative 
2 
 
recent heart failure with additional complication or nonresponse to standard treatments, unexplained 
cardiomyopathy in children, and several other conditions. Noninvasive diagnostic approaches include the 
use of echocardiography, electrocardiograms, cardiac magnetic resonance imaging, and rarely positron 
emission tomography scans2. Clinical symptoms of myocarditis include acute chest pain, new-onset or 
worsening of dyspnea, fatigue, signs of heart failure, palpitations, unexplained arrhythmias, aborted sudden 
cardiac death or unexplained cardiogenic shock. Patients may also be asymptomatic in the presence of 
myocardial inflammation5, 6.  
Treatment strategies depend on the clinical symptoms of the patient, the suspected etiology and the 
disease state2. Conventional medical treatment of heart failure or arrhythmias is generally undertaken. 
Unstable patients will be treated in intensive care units with respiratory and mechanical support, and 
fulminant cases may require ventricular assist devices or extracorporeal membrane oxygenation to bridge 
the patient to recovery or heart transplantation7, 8. Immunosuppressive therapy is indicated in virus-
negative autoantibody-positive patients, where it was shown to benefit a majority of patients9. 
Immunosuppressive drugs are also used in patients with specific etiologies such as giant cell myocarditis or 
eosinophilic myocarditis.  
The main forms of pathogenesis in myocarditis are thought to be viral infection and autoimmunity. These 
forms are not mutually exclusive, as viral infection may progress to post-infectious autoimmune disease 
and patients may have both, viral genomes in endomyocardial biopsies and anti-cardiac autoantibodies10, 
11. Autoantibodies against cardiac antigens are present in the majority of myocarditis patients10. Moreover, 
myocarditis is associated with other autoimmune diseases12. 
Myocarditis can be classified based on histology, etiology, disease stage or extent of myocyte damage (Table 
1). These classifications are partially overlapping and different studies may report different sets of 
classifications, making it often difficult to compare outcomes. The histological subtypes are based on the 
predominant infiltrating cell type detected on endomyocardial biopsies or at autopsy. Lymphocytes 
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accompanied by numerous other cell types predominate in lymphocytic myocarditis. The classification of 
eosinophilic myocarditis seems to be variable with “any”, “numerous” or “predominantly” eosinophils 
being sufficient for the diagnosis. Giant cell myocarditis has very characteristic, large, multinucleated cells 
derived from monocytes and usually severe myocyte necrosis. The etiologies show partial overlap with the 
histological appearance. For example, viral myocarditis is usually thought to be predominantly lymphocytic 
while hypersensitivity myocarditis and parasitic myocarditis are generally eosinophilic and giant cell 
myocarditis is thought to be an autoimmune disease13, 14. However, lymphocytic myocarditis can also be 
autoimmune-mediated. In addition, there is often no identified etiology – many cases of myocarditis are 
idiopathic5, 6.   
Table 1: Subtypes of myocarditis 
Classification Subtypes  
Based on histology Lymphocytic myocarditis  
Neutrophilic/ granulomatous 
Eosinophilic myocarditis 
Giant cell myocarditis 
Sarcoidosis 
Based on etiology Infectious 
- viral (see 13) 
- bacterial 





Based on disease stage Acute myocarditis 
Chronic myocarditis 
Healed myocarditis 
Based on myocyte damage Myocarditis (inflammation and myocyte damage/necrosis) 
Borderline myocarditis (mild inflammation only) 




Eosinophilic myocarditis is a relatively rare subtype of myocarditis that is characterized by eosinophil 
infiltration in the myocardium. The diagnosis is made in a similar way as the diagnosis for myocarditis, with 
the additional criterion of eosinophilic inflammation in the myocardium by histological examination. Often, 
there is an associated increase in blood eosinophils, which may raise the suspicion of eosinophilic 
myocarditis14. However, eosinophilia is not always present15, 16. Eosinophilic myocarditis is usually treated 
with immunosuppressive therapy, or based on the underlying etiology17. Eosinophilic myocarditis can be 
classified according to histopathological characteristics, suspected etiology, or associated clinical conditions 
(Table 2, Table 3). These classifications are partially overlapping and do not encompass all cases, revealing 
the incomplete appreciation of the pathogenesis of eosinophilic myocarditis.  




Allergic reaction (delayed hypersensitivity reaction) to drugs (see Table 3), 
rather than toxic effects of drugs; often typical signs of allergic reactions 
(fever, rash, blood eosinophilia); can result in sudden death; patchy 




Severe, acute form that may be rapidly fatal; may represent the extreme 
form of a hypersensitivity myocarditis, but generally the etiology is 
unknown; intense, diffuse eosinophil and lymphocyte infiltration with 






Eosinophilic endomyocarditis in patients with prolonged high levels of 
blood eosinophils such as in hypereosinophilic syndrome or eosinophilic 
granulomatosis with polyangiitis; characterized by endomyocardial fibrosis, 




Unknown etiology, hypotheses include helminth-induced chronic 
eosinophilia leading to endomyocardial fibrosis similar to the process seen 
in hypereosinophilic syndromes, or toxic agents 
This table is based on14, 18, 19.  
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Hypersensitivity myocarditis is thought to be an allergic delayed type hypersensitivity reaction to drugs, 
rather than a toxic effect14. Some patients present with typical signs of an allergic reaction, such as fever, 
rash, and blood eosinophilia20, 21. Given these unspecific symptoms, hypersensitivity myocarditis may not 
be recognized and can result in sudden death. The first description came from French and Weller, who 
described eosinophilic myocarditis in patients taking sulfonamides within weeks before death22. They also 
showed that sulfonamides administered to rats or mice resulted in a similar eosinophilic myocarditis. 
Numerous drugs have since been associated with eosinophilic myocarditis (Table 3)14, 18, 20, 23.  When 
patients who have recently started taking one of the implicated drugs develops symptoms of an allergic 
reaction, chest pain, or symptoms of heart failure, an endomyocardial biopsy can confirm the presence of 
hypersensitivity myocarditis14, 24. The drug causing the allergic reaction should then immediately be stopped 
and heart failure is treated with standard therapy. Corticosteroids are often initiated as well25. 
Table 3: Possible etiologies of eosinophilic myocarditis 
Group Etiological agents 
Drugs Acetazolamide, amitriptyline, amphotericin B, ampicillin, carbamazepine, 
cefaclor, chloramphenicol, chlorthalidone, clozapine, desipramine, 
hydrochlorothiazide, indomethacin, interleukin (IL)-4, isoniazid, methyldopa, 
oxyphenylbutazone, para-aminosalicylic acid, penicillin, phenindione, 
phenobarbital, phenylbutazone, phenytoin, spironolactone, streptomycin, 
sulfadiazine, sulfisoxazole, sulfononylureas, tetanus toxoid, tetracycline 
Parasites Trypanosoma cruzi, Toxoplasma gondii, Trichinella spiralis, Entamoeba fragilis, 
Isospora belli, Strongyloides spp., Toxocara canis, Toxocara catis, Baylisascaris 
procyonis, Echinococcus, and Schistosoma spp., visceral larva migrans of certain 
Nematode species 
Eosinophilia Hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis 
This table is based on14, 19, 23, 24, 26. 
 
Acute necrotizing eosinophilic myocarditis is a very severe form of eosinophilic myocarditis. It presents with 
an acute onset of fever, rash, severe chest pain, and heart failure27, 28 and may simply represent the most 
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severe forms of hypersensitivity myocarditis28. Acute necrotizing eosinophilic myocarditis is also found in 
patients with drug rash with eosinophilia and systemic symptoms (DRESS)29, 30, a general term for severe 
allergic reactions to drugs with systemic involvement that may also affect other organs than the heart. 
Given the severe heart failure symptoms and high mortality, patients are treated aggressively with high 
doses of corticosteroids and sometimes additional mechanical support such as ventricular assist devices or 
extracorporeal membrane oxygenation. If patients survive the acute phase, complete recovery is possible29, 
31.  
Eosinophilic myocarditis occurs frequently in patients with prolonged hypereosinophilia (blood eosinophils 
>1500/µl), as in hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis 
(EGPA). Cardiac involvement in these patients is a major contributing factor to morbidity and mortality32, 33. 
HES usually causes eosinophilic endomyocardial fibrosis and thrombus formation33, 34. The disease is 
thought to evolve in 3 stages, beginning with acute myocarditis with myocyte necrosis, vascular 
inflammation, and damage of the endocard by eosinophils. In the second stage thrombi form on the 
damaged endocard and can obstruct large parts of the ventricles. Finally, thrombi are replaced by fibrosis 
which may also involve the valves33. Patients often don’t show symptoms in the first stage and may not 
develop heart failure until the final stage, at which point both restrictive and dilated cardiomyopathies are 
possible33. Patients with EGPA can develop eosinophilic myocarditis, eosinophilic vasculitis of the heart and 
endomyocardial fibrosis35. 
Eosinophilic myocarditis in association with parasitic infections is thought to be a result of sustained high 
blood eosinophilia rather than direct infection of the heart with parasites36, although some parasites can 
directly infect the heart26, 37. Parasites that may cause eosinophilic myocarditis are listed in Table 3. Tropical 
endomyocardial fibrosis accounts for a striking proportion of heart failure in some endemic regions of Sub-
Saharan Africa and was also reported in South America and Asia38. The clinical presentations are similar to 
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those of patients with HES19, 38. Etiology is unknown and hypotheses range from infectious (parasitic) causes 
over nutritional deficiencies and toxins to the damaging effect of prolonged eosinophilia38.  
The high frequency of endomyocardial damage in patients with prolonged eosinophilia and cases of acute 
necrotizing myocarditis where eosinophils are found next to necrotic myocytes have given rise to the idea 
that eosinophils may be particularly pathogenic in the heart39-42. Several mechanisms have been proposed. 
Eosinophils may be directly cytotoxic to cardiomyocytes39, 43, 44, activate cardiac mast cells45, or release pro-
thrombotic tissue factor46. However, these studies are not mechanistic and the true pathological effects of 
eosinophils in the heart remain to be discovered.  
Dilated cardiomyopathy 
Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by “dilation and impaired contraction of 
the left or both ventricles that is not explained by abnormal loading conditions or coronary artery disease. 
DCM includes idiopathic, familial/genetic, viral and/or immune, alcoholic/toxic subtypes.”2. This recent 
definition from the World Health Organization / International Society and Federation of Cardiology 
highlights the large and heterogenous group of disorders defined by a common morphological abnormality 
and the failure of myocardial performance. Diagnosis is made by echocardiography or cardiac magnetic 
resonance imaging showing a decrease in left ventricular ejection fraction and dilation of the left ventricle 
at the end of diastole to a Z score of >2 standard deviations47.  
One of the causes of DCM is myocarditis, which is responsible for about 9-16% of cases with new onset 
DCM (see Figure 1 and discussion in Chapter 2)48-50. How myocarditis progresses to DCM is not completely 
understood. Replacement of the inflammatory infiltrate with fibrotic tissue, destruction of myocytes, and 
remodeling of the extracellular matrix likely play a role51. There are also numerous other etiologies of DCM: 
genetic diseases, drugs, toxins, endocrinological diseases, nutritional deficiencies, electrolyte disturbance, 
infections, autoimmune diseases (including myocarditis), and peripartum cardiomyopathy (Table 4). 
8 
 
Monogenetic traits as well as complex genetic traits are the most common cause of DCM52. Familial disease 
accounts for about 20-35% of cases53. Genetic predisposition can also interact with environmental factors47.  
 
 
Figure 1: Autoimmune myocarditis can progress to inflammatory dilated cardiomyopathy  
 
Clinical evaluation of patients with suspected DCM includes a detailed medical history, family history for 
the evaluation of genetic causes, and detailed physical examination which may provide clues about the 
etiology as well as the severity of disease and the patient’s prognosis54. Diagnostic tests include complete 
blood counts, urinalysis, serum electrolytes, liver function tests, biomarkers, etc. Imaging and assessment 
of cardiac function are also done through electrocardiograms, echocardiograms, and sometimes magnetic 
resonance imaging47, 54. The latter allows visualization of inflammatory processes or scars in the 
myocardium which will be the case in DCM caused by myocarditis. In patients with clinically suspected 





Table 4: Etiologies of dilated cardiomyopathy 
Group Agent / subtype / disease 
Genetic Titin, lamin A/C, myosin heavy chain, troponin T, myosin-binding protein C, RNA-
binding motif-20, myopalladin, sodium voltage-gated channel alpha subunit 5, 
BaCl2-associated athanogene 3, phospholamban, dystrophin, tafazin  
Drugs Anthracyclines, antimetabolites, alkylating agents, Taxol, 
hypomethylating agents, monoclonal antibodies, tyrosine 
kinase inhibitors, immunomodulating agents, clozapine, olanzapine, 
chlorpromazine, risperidone, lithium, methylphenidate, tricyclic antidepressants, 
Chloroquine, all-trans retinoic acid, antiretroviral agents, phenothiazines 
Toxins Ethanol, cocaine, amphetamines, ecstasy, arsenic, cobalt, steroids 
Nutritional 
deficiencies 
Selenium deficiency, thiamine deficiency, zinc and copper deficiency, carnitine 






Hypothyroidism, hyperthyroidism, Addison disease, phaeocromocytoma, 
acromegaly, diabetes mellitus 
Infection  Viral, bacterial, mycobacterial, fungal, parasitic 
Autoimmune 
diseases 
Autoimmune myocarditis, polymyositis, dermatomyositis, eosinophilic 
granulomatosis with polyangiitis, granulomatosis with polyangiitis, systemic lupus 
erythematosus, sarcoidosis 
Peripartum  Peripartum dilated cardiomyopathy 
This table was adapted from47.  
 
Therapy follows the general recommendation for heart failure patients by the American College of 
Cardiology and the American Heart Association54 or the European Society of Cardiology guidelines for 
chronic heart failure55. Specific etiologies may warrant additional treatments. For example, genetic 
counseling and screening of relatives is conducted in genetic forms of DCM. DCM caused by myocarditis 
should be treated according to current guidelines for systolic heart failure and additional 
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immunosuppression in the case of eosinophilic or giant cell myocarditis and cardiac sarcoidosis56. 
Intracardiac devices may be implanted in DCM patients to prevent sudden cardiac death54. 
Experimental autoimmune myocarditis 
Animal models are necessary to study the complex interplay between the immune system and the heart to 
generate mechanistic insights that will eventually improve diagnosis and therapy of myocarditis in humans. 
The main mouse models of myocarditis are Coxsackievirus B3 (CVB3) myocarditis and experimental 
autoimmune myocarditis (EAM).  
The murine CVB3 myocarditis model has been used to study viral myocarditis for over 40 years57. Depending 
on the host strain, CVB3 can induce transient or persistent myocarditis of different severity58. Strains with 
persistent myocarditis also develop autoantibodies against cardiac antigens. This led to the development 
of the EAM model, where mice are immunized with cardiac myosin in Complete Freund’s Adjuvant (CFA) 
generating an autoimmune response against the heart resulting in autoimmune myocarditis59.  
Since its development in the 1980s the EAM model has been refined and today synthetic immunodominant 
peptides are used for the induction of autoimmune myocarditis60. The immunodominant peptide for BALB/c 
mice is the cardiac myosin heavy chain α peptide 614-629 (SLKLMATLFSTYASAD)61. To induce disease, 100 
µg peptide is emulsified in CFA supplemented to 5mg/ml with heat-killed Mycobacterium tuberculosis and 
injected subcutaneously on days 0 and 7 into susceptible mouse strains. On day 0, mice also receive an 
intraperitoneal injection of 500 ng pertussis toxin60. The use of CFA on both day 0 and day 7 is absolutely 
required to induce disease (Jillian Fontes, Jobert Barin, Monica Talor, Noel Rose and Daniela Čiháková, 
unpublished observations). Substituting CFA for either incomplete Freund’s Adjuvant or Alum adjuvants in 
either or both injections is not sufficient to induce disease, highlighting the strong inherent tolerance to 
cardiac antigens that has to be overcome.  
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In our studies, BALB/c mice are used, which develop myocarditis of intermediate severity and progress to a 
chronic stage with DCM (Figure 2)12. The first 10 days are the induction phase during which an adaptive 
immune response to cardiac myosin is established. Infiltration of the myocardium with immune cells begins 
around day 10-12, marking the beginning of the acute myocarditis phase. Autoreactive T cells as well as 
numerous other immune cells infiltrate the heart and autoantibodies can be detected in the serum. 
Inflammation peaks around day 21 post immunization and declines thereafter. In most mice inflammation 
resolves thereafter, but occasionally chronic inflammation can be observed as late as day 60. Following the 
acute myocarditis phase, inflammation is replaced by fibrosis and activation of tissue remodeling processes. 
During the chronic phase mice develop DCM, which can be detected by echocardiography.  
 
Figure 2: Model of experimental autoimmune myocarditis in BALB/c mice 
At days 0 and 7, mice are immunized with cardiac myosin heavy chain α peptide 614-629 in Complete 
Freund’s Adjuvant. On day 0, mice also receive 500 ng pertussis toxin. Myocarditis and DCM develop in 3 
phases: induction, acute myocarditis, and chronic DCM. Abbreviations: DCMi, inflammatory dilated 
cardiomyopathy. 
Eosinophils 
Eosinophils are multifunctional granulocytes that develop in the bone marrow in response to IL-5, with a 
minor role for IL-3, GMCSF, and IL-3362-65. IL-5 also mediates the release of mature eosinophils into the 
bloodstream  from where they migrate into tissues66. In healthy individuals, eosinophils are found in the 
bone marrow, blood, spleen, thymus, gastrointestinal tract, and uterus67. Under pathological conditions, 
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eosinophils can infiltrate other tissues as well. Eosinophils are usually enumerated in the blood because 
tissue eosinophils are hard to measure. Eosinophil counts over 450 to 500 cells / µl blood are considered 
mild eosinophilia and counts over 1500 cells /µl are characterized as hypereosinophilia68.  
The main chemotaxins for eosinophils are eotaxins, which homeostatically recruit eosinophils to the 
gastrointestinal tract, thymus, and uterus69-71 and to other organs in disease states72-74. Humans express 
three functional eotaxins (CCL11, CCL24, CCL26) whereas mice only express two (CCL11 and CCL24)75-78. The 
eotaxin receptor, CCR3, is highly expressed on eosinophils and to a low level on human basophils, mast cells 
and Th2 cells (Figure 3)79, 80. Other eosinophil chemoattractants include CCL5 and lipid media-tors such as 
leukotriene B4 and prostaglandin D2, although these factors are not specific for eosinophils81.  
A unique characteristic of eosinophils are their large specific granules, which contain four major granule 
proteins and numerous cytokines, chemokines, and growth factors (Figure 3)81. Cytotoxic effects to host 
tissues and pathogens have been demonstrated for all major granule proteins: eosinophil cationic protein 
(ECP), eosinophil-derived neurotoxin (EDN), eosinophil peroxidase (EPX), and major basic protein (MBP)82. 
MBP is highly cytotoxic to mammalian cells, helminths and bacteria due to its disrupting of the cell 
membrane83-85. Other effects of MBP include altering of smooth muscle contraction, inducing mast cell and 
basophil degranulation, and provoking peripheral nerve plasticity86-89. The granule proteins ECP and EDN 
are ribonucleases63, 90 with neurotoxic and strong antiviral activities91, 92 as well as immune modulatory 
functions93. EPX generates reactive oxygen species that are directed extracellularly94. These products have 
cytotoxic, prothrombotic, and proinflammatory effects94-96. Granule contents are generally preformed in 
eosinophils and released upon stimulation. Piecemeal degranulation is the most common process by which 
eosinophils release their granule contents97-99. Specific granule factors, rather than the entire granule, are 





Figure 3: Cellular structure, receptors and mediators of eosinophils.  
The pseudocolored composite electron micrograph of an eosinophil highlights cellular structures. 
Characteristic features of eosinophils include the multilobed nucleus, specific eosinophil granules with an 
electron-dense core and an electron-lucent matrix, lipid bodies, and sombrero vesicles. Eosinophil granules 
contain cationic proteins, cytokines, growth factors, chemokines and enzymes. The granule contents can 
be released upon stimulation. Lipid bodies are the place of synthesis for numerous lipid mediators. Granule 
contents can be released through sombrero vesicles. Eosinophils carry numerous cell surface receptors 
including chemokine receptors, Fc receptors, pattern recognition receptors, receptors for lipid mediators, 
cytokine receptors, complement receptors, and adhesion receptors. Abbreviations: 15-HETE, 15-
hydroxyeicosatetraenoic acid; APRIL, a proliferation-inducing ligand; CCL, CC-chemokine ligand; CCR, CC-
chemokine receptor; CXCL, CXC-chemokine ligand, CXCR, CXC-chemokine receptor; ECP, eosinophil cationic 
protein; EDN, eosinophil-derived neurotoxin; EGF, epidermal growth factor; EPX, eosinophil peroxidase; 
GMCSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; MBP, major basic protein; NGF, 
nerve growth factor, PDGF, platelet-derived growth factor; PAF, platelet activating factor; SCF, stem cell 




Chapter 2: Epidemiology of myocarditis and dilated cardiomyopathy 
Myocarditis 
Global burden of myocarditis 
The writing group on myocarditis for the Global Burden of Diseases, Injuries and Risk Factors 2010 study 
concluded that accurate, population-based estimates of the incidence or prevalence of myocarditis were 
not available in any world region100. As a result, myocarditis was reported together with cardiomyopathies 
as “cardiomyopathy and myocarditis” in the Global Burden of Disease 2010 study and still is reported as 
such in the 2015 study (Figure 4). Cardiomyopathies and myocarditis accounted for 9.2 million or 0.37% of 
disability-adjusted life years (DALYs) in 2015101. The writing group also concluded that myocarditis is 
responsible for 0.5% to 4% of prevalent heart failure, varying by age and region100. A recent review analyzing 
the cardiovascular diseases of the poorest billion of the world population summarizes causes of heart failure 
in Sub-Saharan Africa102. Cardiomyopathies likely account for about 38% of rural and 22% of urban cases of 
heart failure in this region. An analysis of the ninth version of the International Classification of Diseases 
codes estimated the global prevalence of myocarditis to be ≈22 of 100 000 patients annually103. 
Overall, there is not enough information to compare regional differences in incidence or prevalence of 
myocarditis or to compare etiologies, risk factors or outcomes with certainty100. Endomyocardial biopsies 
and cardiac magnetic resonance imaging, the diagnostic tests for myocarditis, are not widely available 
around the world, restricting the ability to identify myocarditis and analyze risk factors and outcomes. Most 
studies were conducted in North America and Europe and in these countries clinical trials are conducted to 
test diagnostic strategies and treatments. Given the invasive nature of endomyocardial biopsies, this 
diagnostic test cannot be employed in large scale or cross-sectional studies. Noninvasive tests are needed 




Figure 4: Estimated disability-adjusted life years lost due to cardiomyopathy and myocarditis in 2015 
Number (top) and percentage of total (bottom) of disability-adjusted life years lost from cardiomyopathy 






Natural history of myocarditis 
Due to the heterogeneity of clinical presentations, myocarditis is difficult to diagnose105.  The gold standard 
for diagnosis is an endomyocardial biopsy; however, these are not often performed or may have a low 
sensitivity because of the focal nature of the inflammatory infiltrate106. This makes it difficult to identify 
cases and determine the frequency of the possible outcomes of myocarditis. Some patients with acute 
myocarditis will recover completely, while others will go on to develop chronic myocarditis or dilated 
cardiomyopathy (DCM)2. Acute myocarditis, both symptomatic and asymptomatic, can also result in sudden 
cardiac death107. Patients who progress to chronic myocarditis / DCM may require heart transplantation or 
die as a result of the disease later on (Figure 5).  
 
Figure 5: Possible outcomes of myocarditis.  
Adapted from2. The frequency of the different outcomes of acute myocarditis are not exactly known, but 
estimates suggest that about 60% may recover, about 15-20% go on to develop dilated cardiomyopathy, 
and the remaining 20-25% will either require a heart transplant or die (for references see text).  
 
Many cases of myocarditis are thought to resolve, yet the exact frequency of patients who heal without 
sequelae is not known. In a short-term study conducted on pediatric myocarditis patients in the U.S., 62 
out of 514 patients (59.6%) had recovered cardiac function by dismissal108. This study did not follow up 
patients beyond hospital dismissal and it is unclear whether recovered cardiac function is equivalent to 
healed myocarditis. In another study on pediatric myocarditis patients, 71 / 119 patients (60%) achieved 
normalized cardiac function by 5 years 109.  
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In up to 30% of cases, myocarditis can progress to DCM2. A review of smaller studies found that on average 
21% of myocarditis patients progress to DCM, though the estimates varied widely110. In children with 
myocarditis about 14% had persistent functional abnormalities over a 3.1 year median follow-up period109. 
Importantly, many episodes of myocarditis are subclinical and thus go undiagnosed, making it difficult to 
estimate the proportion of myocarditis patients that progress to DCM106. In contrast, the frequency of 
myocarditis as a cause of DCM has been addressed in large studies. In a study at Johns Hopkins with over 
1,200 DCM patients seen between 1982 and 1998, myocarditis was identified as the cause in 9.2%111. In 
children diagnosed with DCM between 1995 and 2003 from the US and Canada, DCM was caused by 
myocarditis in 15.6%112. In both of these studies, no cause was identified in about 50% of the DCM patients, 
suggesting that myocarditis could account for an even higher proportion of DCM cases. 
Myocarditis can result in sudden death or progress to chronic myocarditis and heart failure, which may lead 
to death later on.  In an Italian study on 174 adult myocarditis patients (mean age 36±18 years) with biopsy-
proven myocarditis, transplant-free survival was 74% at 6 years10. A smaller study from Korea with 54 
patients with biopsy-proven myocarditis reported all-cause mortality of 20.4% after a median follow up of 
10.4 years (mean 9.7±5/7 years)16. A U.S. study on 112 myocarditis patients (mean age 47.3±15 years) from 
1978 to 2002 stated a transplant-free survival rate of 56% at 5 years113. For pediatric myocarditis patients 
in the U.S., transplant-free survival was 74% by 5 years (88 /119 patients)109. A large fraction of the 
deaths/heart transplantations likely happen early after myocarditis diagnosis in children. A retrospective 
analysis of 514 pediatric acute myocarditis cases from 2006-2011 in the U.S. with a median length of 
hospital stay of 7 days (IQR: 3-19 days) showed that 21 (4.1%) received heart transplantation and 37 (7.2%) 
had died at the time of discharge108. 
Taken together, these studies suggest that of those patients diagnosed with myocarditis, about 60% may 
recover, about 15-20% go on to develop DCM, and the remaining 20-25% will either require a heart 
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transplant or die. These proportions may vary by age, sex, ethnicity or location, but sufficient data are 
unavailable to evaluate these differences. 
Fatal myocarditis 
Given the wide range of clinical presentations of myocarditis, it is thought to often go undiagnosed or 
mistaken for other, more common cardiac diseases. Therefore, autopsy series offer a unique possibility of 
assessing the frequency of myocarditis in deceased individuals. An unselected autopsy series from Italy 
reports 31 cases (5.1%) of histological myocarditis out of 605 necropsies performed114. The highest rate of 
myocarditis was found in 30-49-year-olds. Interestingly, none of these cases were suspected clinically. The 
subtype of myocarditis was also determined: 11 cases of lymphocytic myocarditis, 16 cases with 
granulocytic infiltrate, and 4 other cases. Another single-center, unselected autopsy series from the UK 
reported the frequency of myocarditis in children 0-18 years of age107. Over a 10-year period 1516 autopsies 
were performed and 28 cases of histological myocarditis (1.8%) were found. The majority of cases were 
detected in children under 1 year of age, but, as a proportion of deaths, myocarditis was more common in 
older children (5-8% of deaths in children 5-18 years of age). The majority of children with histological 
myocarditis died sudden deaths either without any preceding symptoms or with non-specific symptoms 
that were not recognized as life-threatening. Only 2 of the 28 cases had clinical features of DCM. All cases 
were classified as lymphocytic myocarditis. These 2 series highlight the discrepancy between lifetime 
diagnosis of myocarditis and frequency of histological myocarditis at death. Given the lack of reliable 
epidemiological data on the incidence of myocarditis, it is not possible to compare the incidence with the 
frequency of myocarditis at death or to estimate the mortality rate for myocarditis. However, these autopsy 
series show that myocarditis is not an uncommon finding in deceased children and young adults, particular 
among those who die sudden unexpected deaths. Whether or not myocarditis was the primary cause of 
death in these individuals cannot be determined with certainty, and it is possible that at least in some cases, 
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myocarditis was an incidental finding and did not contribute to death. In those who died of sudden deaths, 
myocarditis is more likely to have been the cause of death. 
Several other studies have analyzed cases of sudden death or sudden cardiac death for the presence of 
myocarditis. Thus, they were preselected on the circumstances of death, in contrast to the above-
mentioned autopsy series which were unselected. Recently, a large autopsy series of adult cases was 
conducted in China115. Among 14,487 autopsies, 553 cases of sudden cardiac death were identified and 
analyzed for the presence of myocarditis by histology. Myocarditis was present in 82 cases (14.8% of sudden 
cardiac death cases). This would correspond to 0.6% of all autopsies, but only those identified as sudden 
cardiac death cases were screened for the presence of myocarditis. An additional 14 cases (2.5% of sudden 
cardiac death cases) were identified as DCM. Myocarditis was more frequent in the young: 35% of 18-34-
year-olds, 8% of 35-54-year-olds, and 3% of 55-80-year-olds. DCM was also detected more frequently in 
younger adults: 6-7% in 18-54-year-olds and less than 1% among 55-80-year-olds. In an autopsy series 
conducted in Sydney between 1994-2002, autopsies of children and young adults (age 0-35 years) were 
analyzed116. Out of 2986 autopsies, 193 were classified as sudden cardiac deaths. Among those, 23 cases of 
myocarditis (12%) were detected.  This would correspond to 0.77% of all autopsies, but only those identified 
as sudden cardiac death cases were screened for the presence of myocarditis. Another study determined 
the frequency of myocarditis in non-traumatic sudden deaths among U.S. military recruits117. Over 6 million 
men and women age 18-35 were monitored and 126 non-traumatic sudden deaths were recorded. Thirteen 
cases (10%) were due to myocarditis. This would correspond to an incidence rate of 1.3/100,000 person-
years, though only those identified as sudden non-traumatic deaths were screened for myocarditis. 
Importantly, military recruits had already passed a physical examination and medical history screening. An 
autopsy series in the State of Maryland published this year reviewed all sudden unexpected deaths from 
January 2005 to December 2014118. Out of 62,130 sudden unexpected deaths, 14,733 were autopsied. Of 
these, myocarditis was determined to be the primary cause of death in 103 cases (0.70%). Myocarditis 
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subtypes were as follows: lymphocytic myocarditis (56, 54%), neutrophilic (23, 22%), eosinophilic (13, 
12.6%), giant cell (2, 1.9%). The mean age at death was 31±17 years and the median age of death was 30 
years. Forty-one (40%) of myocarditis cases also had ventricular dilation. In the State of Indiana from 1987 
to 1991 the frequency of myocarditis in autopsies was 0.6%119 and in the State of Michigan it was reported 
to be 1.3% in the years from 1996 to 2004120. Based on death-certificate records from Finland, the incidence 
rate of fatal myocarditis is 0.46 / 100,000 person-years or 639 cases (0.047%) of 1.35 million deaths 
between 1970 and 1998121. Confirming other studies, the authors found that the proportion of deaths 
caused by myocarditis was highest in children and adults under 45 years of age (up to 0.64% of deaths in 1-
4-year-olds). This study is unique in that it provides a frequency of myocarditis of all deaths, while most 
other studies have already preselected on sudden or cardiac deaths. However, the sensitivity and specificity 
of death-records for myocarditis as a cause of death has not been established.  
Overall, these studies show very similar frequencies of myocarditis as a proportion of sudden deaths, 
ranging from 10.0% to 14.8% in children and young adults. The estimates for myocarditis as a frequency of 
all autopsied deaths in children and young adults varies more widely, from 0.6% to 5.1%, although most 
estimates are closer to under 1%.  Both the percentage of fatal myocarditis as a proportion of total deaths 
as well as the absolute number of recorded fatal myocarditis cases are highest in children and young adults. 
Most studies show that in this group, myocarditis may be responsible for close to 1% of deaths.  
Sex and age differences 
Both myocarditis and DCM are more frequently diagnosed in males than in females122. The female / male 
ratio in myocarditis trials and cohorts was reported between 1:1.5 and 1:1.710, 113, 123. Men are also at a 
higher risk of fatal myocarditis than women. In a study conducted in Finland, the odds ratio of fatal 
myocarditis was 1.34 (95% CI: 1.15-1.58, p<0.001) for men compared to women121. In a study on recent-
onset DCM and myocarditis, transplant-free survival was better in women than in men (4-year transplant-
free survival of 96% versus 84%, p=0.003) over a mean follow up of 2.2±1.4 years124. In children with 
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myocarditis, sex was not associated with mortality108. Improvement of cardiac function is also less likely for 
males than for females. Recovery of cardiac function in patients with recent-onset idiopathic DCM or 
myocarditis with left ventricular ejection fraction under 40% after 6 months was significantly better for 
women than for men 34% versus 20%, p=0.004)124. Animal models show similar effects of sex on myocarditis 
severity. Male BALB/c mice have increased CVB3-induced myocarditis122 and increased severity in 
experimental autoimmune myocarditis.  
There is a strong association of myocarditis with age. Among pediatric cases with acute myocarditis, the 
number of cases peaks in infancy and in mid-teenage years108. Mortality rates are higher in younger children 
compared to older children108 and most fatal myocarditis cases are detected in infants107, 121. Another peak 
of myocarditis is in young adults114, 115, 118, 121.  
Chagas 
Chagas disease is one of the most common causes of non-ischemic cardiomyopathy in Central and South 
America. Five to eighteen million people are infected with the protozoan Trypanosoma cruzi, the causative 
agent, resulting in over 10,000 deaths per year125. Chagas disease predominantly affects the poor living in 
rural areas102. Due to migration, it now also affects over 300,000 infected individuals in the United States126. 
Chagas disease occurs in 3 phases125. The acute phase is typically asymptomatic but can cause fever and 
malaise in a small proportion of infected individuals. The intermediate phase is asymptomatic and over 50% 
of individuals will remain in this phase. About 20-30% will progress to chronic cardiovascular Chagas disease 
(or Chagas cardiomyopathy) after over a decade and others may develop chronic digestive sequela127. The 
clinical manifestations of cardiovascular Chagas disease include left ventricular dilation, myocarditis, 
congestive heart failure, conduction abnormalities, ventricular arrhythmias, thromboembolic disease and 
sudden cardiac death126. Mortality from Chagas disease is predominantly due to cardiac involvement.  
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Myocarditis as a rare complication in common infectious diseases and vaccines 
Myocarditis is frequently caused by viral infections, particularly from the genus of enteroviruses (eg. 
Coxsackievirus B3, Parvovirus B19)13. In addition, myocarditis can be observed as a rare complication of 
common viral infections. In an autopsy series on 51 AIDS patients from Mexico, myocarditis was found in 5, 
pericarditis in 7, and endocarditis in 6 cases128. HIV-associated heart failure is common among people living 
with HIV129. In the pre-antiretroviral therapy era, HIV-associated heart failure was related to severe 
immunocompromise and had a median survival of about 100 days after diagnosis130. Today, there are 
several proposed hypotheses for HIV associated heart failure: direct myocardial damage through HIV 
infection of cardiomyocytes (which has been shown in vitro), mitochondrial damage in cardiomyocytes, 
opportunistic infections (due to immune compromise) that cause myocarditis, micronutrient deficiencies 
(particularly selenium), toxicity of antiretroviral therapy, or autoimmunity129. In the era of antiretroviral 
therapy, HIV infection continues to increase heart failure mortality131. The Heart of Soweto study revealed 
that patients with HIV-related cardiomyopathy had higher viral load and lower CD4+ T cell counts than 
people living with HIV without heart failure131. 
Myocarditis has also been associated with dengue virus infections. In a Colombian study of 102 children 
with dengue, 11 children (13%) showed symptoms of myocarditis and 1 fatal case showed widespread 
infection of the heart with dengue132. Myocarditis can also be a rare complication of mumps133 and was 
associated with the H1N1 influenza epidemic in 2009 in Japan134. In a prospective study on recipients of the 
smallpox vaccine, 10% were found to have new-onset chest pain, dyspnea or palpitations and 2.7% were 
found to have possible subclinical myocarditis within 30 days of vaccination135. In addition to the viral 





The most common histopathological form of myocarditis is lymphocytic myocarditis. As a result, most of 
the findings discussed above are either exclusively on lymphocytic myocarditis or, if the subtype was not 
defined, they are to a large part based on patients with lymphocytic myocarditis. Since the focus of this 
dissertation is on eosinophils in myocarditis, lymphocytic myocarditis will only be discussed briefly. 
Viral infections and autoimmune reactions are the most common causes of lymphocytic myocarditis (see 
Chapter 1). Among patients with acute lymphocytic myocarditis, those with circulating autoantibodies 
against cardiac antigens are most likely to benefit from immunosuppressive treatment (improvement of 
left ventricular ejection fraction), while those with viral genomes in the heart are likely not to respond136, 
137. This highlights how the role of the immune system in myocarditis varies depending on the etiology of 
the disease.  
A large study from Australia on childhood DCM analyzed the frequency of lymphocytic myocarditis138. 
Frequency of lymphocytic myocarditis in pediatric DCM was 35%. Six of 9 cases who presented with sudden 
death (33%) had lymphocytic myocarditis. For those who underwent endomyocardial biopsy in the first two 
months after presentation, the rate of lymphocytic myocarditis was even higher at 40%139. Despite this high 
initial mortality, long-term survival was better for children with lymphocytic myocarditis than for those with 
nonspecific histological findings138. The likelihood of survival was also addressed in a large single-center 
series of biopsy-proven myocarditis from Massachusetts General Hospital113. Of 112 consecutive patients 
with histopathologic confirmation of myocarditis, 88 (79%) were alive without cardiac transplantation at 1 
year and 63 (56%) at 5 years. Among those with lymphocytic myocarditis (55%) transplant-free survival for 
patients was 80% at 1 year, 50% at 5 years and, 45% at 10 years. Compared to patients with borderline 
myocarditis, survival was much worse for patients with lymphocytic myocarditis. In contrast to the studies 
above from Australia, this population included adults. The mean age was 47±15.7 years. A large case series 
of patients undergoing heart transplantation looked at the prognosis for patients with lymphocytic 
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myocarditis in the explanted hearts140. Out of 32 patients with histological evidence of lymphocytic 
myocarditis in the explanted heart, only 6 (19%) had been clinically diagnosed with myocarditis. The 
majority (20 patients, 63%) had been diagnosed with idiopathic DCM. The prognosis for patients with 
lymphocytic myocarditis in explanted hearts was compared to age- and gender-matched controls with 
either idiopathic DCM or ischemic cardiomyopathy (based on clinical diagnosis). Survival post 
transplantation was not significantly different between the 3 patient groups. The 5-year survival rate post 
transplantation for lymphocytic myocarditis patients was 86% in this study. However, lymphocytic 
myocarditis patients had a higher frequency of acute cellular rejections compared to those with ischemic 
cardiomyopathy. More studies will be needed to establish the prognosis for patients with heart 
transplantations based on the etiology of the underlying cardiomyopathy. 
Eosinophilic myocarditis 
Endomyocardial biopsies of myocarditis patients are often not performed, or the histopathological type of 
myocarditis is not reported. Therefore, it is very difficult to identify the subtype of myocarditis and the 
prevalence or incidence of eosinophilic myocarditis cannot be estimated. In studies where histopathological 
types are reported, eosinophilic myocarditis varies from 2% - 22.6% of all myocarditis cases16, 113, 118, 141. In 
a large study in Maryland, eosinophilic myocarditis accounted for 12.6% of all fatal myocarditis cases118. 
Eosinophilic myocarditis is less common than lymphocytic myocarditis but more frequent than giant cell 
myocarditis. It is unclear whether there are age or gender differences among eosinophilic myocarditis 
patients. Eosinophilic myocarditis has numerous possible etiologies (see Chapter 1, Table 3), many of which 




Mortality in eosinophilic myocarditis 
It is not known what proportion of eosinophilic myocarditis patients will require heart transplantations or 
die from this disease. A compilation of several studies with at least 3 biopsy-proven eosinophilic myocarditis 
patients yields an overall transplant-free survival rate of 90% (Table 5). However, many studies did not 
report the time of follow-up and the underlying causes may not be representative of the true distribution. 
A recent study from Korea suggests that patients with eosinophilic myocarditis may fare better than 
lymphocytic myocarditis patients16. Of 54 patients with biopsy-proven myocarditis, 29.6% were 
lymphocytic, 22.2% eosinophilic, and 48.1% borderline myocarditis. Underlying causes of eosinophilic 
myocarditis were not assessed. The median follow up for all patients was 10.4 years. Five (42%) of 
lymphocytic myocarditis patients died but none of the eosinophilic myocarditis patients. A study from Japan 
reported on 7 patients with eosinophilic myocarditis identified among 64 patients admitted with 
eosinophilia over a 27-year period142. The etiologies were identified as follows: 3 idiopathic, 2 eosinophilic 
granulomatosis with polyangiitis (EGPA), 1 parasitic infection (Toxocara canis), 1 chronic eosinophilic 
leukemia (hypereosinophilic syndrome, HES). Six out of 7 patients were alive at the end of the study with a 
mean survival time of 37 ±40 months. Another Japanese case series excluded patients with EGPA, HES, or 
allergic myocarditis (although the criteria used for diagnosis were not clear), leaving only patients with 
idiopathic eosinophilic myocarditis (n=22) and lymphocytic myocarditis (n=7)143. None of the patients had 
died one year after discharge. In a relatively large study with 112 myocarditis patients (62 lymphocytic, 25 
borderline, 11 granulomatous, 7 eosinophilic, 7 giant cell), six patients underwent cardiac transplantation 
within the first year113. Of these six, four had eosinophilic myocarditis, 1 had giant cell myocarditis, and 1 
had granulomatous myocarditis. Thus, 4/7 eosinophilic myocarditis patients required heart transplantation 
within one year of diagnosis. These studies report vastly different transplant-free survival rates for 
eosinophilic myocarditis, from 100% over 10 years to less than 50% in one year, making it impossible to 
draw conclusions on the expected survival rate. Several factors like treatments strategies, underlying 
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etiology, additional co-morbidities, or patient characteristics may explain the differences between studies 
and should be explored further. 
Table 5: Reported mortality in eosinophilic myocarditis 





(survived / total) 
Sohn et.al., 2015 146 4 HES (2) 
Parasitic (2) 
n.a. 4/4 
Youn et.al., 201416 12 n.a. 10±4 12/12 
Comarmond et.al., 201332 63 EGPA (63) 5 58/63 





Yanigasawa et.al., 2011143 22 Idiopathic (22) 1 22/22 
Al Ali et.al., 2006147 3 Hypersensitivity (1) 
Idiopathic (2) 
n.a. 3/3 
Magnani et. al., 2006113 7 n.a. 1 3/7 
Starza et.al., 2005148 4 HES (4) 4.9±8 (4) 4/4 
Vandenberghe et.al., 2004149 3 HES (3) 3.8±1.1 2/3 
Arima et.al., 2002150 5 n.a. n.a. 4/5 
Vargo et.al., 1977151 3 Parasitic (3) n.a. 1/3 














Numerous drugs have been reported as the potential cause of hypersensitivity myocarditis (Table 3). The 
frequency of this complication has only been reported for a few drugs, such as clozapine. An incidence of 
0.7-1.2% has been reported for clozapine-induced myocarditis144. Symptoms start around 3 weeks from 
drug initiation. Out of those patients, 10% died, about half recovered and 15% showed persistent left 
ventricular dysfunction. For the remaining 25% no follow-up information was available145. Drug rash with 
eosinophilia and systemic symptoms (DRESS) is a systemic hypersensitivity reaction to drugs with a 5-10% 
fatality rate29. In a review of 22 reported cases with myocarditis, 12 (55%) died, another 2 (9%) had 
continued cardiac insufficiency and the remaining patients (36%) recovered29. Hypersensitivity myocarditis 
is a rare but life-threatening complication of numerous drugs. For most agents, the frequency of this 
complication is unknown and the causative agent cannot always be identified unequivocally. More research 
is required to identify patients who may be at risk of this side effect. 
Hypersensitivity myocarditis in heart transplantations 
In heart transplant patients, findings of eosinophilic myocarditis in the explanted heart are not 
uncommon152-155. This is thought to be a hypersensitivity reaction to drugs as patients awaiting heart 
transplants usually take a multitude of drugs to sustain them until a donor is found. The first report on 
eosinophilic myocarditis in a large cohort of transplant patients was published in 1991152. Among 193 heart 
transplant patients, 15 (7%, 13 male, 2 female) had eosinophilic myocarditis. Interestingly, none of these 
were detected clinically, which the authors attribute to the already severe cardiac conditions of these 
patients, making it difficult to observe a worsening in heart function. Another study, however, did report 
worsening of cardiac function in 3 patients156. Of the 15 cases, 14 developed eosinophilia within 2 weeks 
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prior to transplant152. All cases had received multiple drugs, which were thought to have provoked 
hypersensitivity myocarditis. Another 2 recent reports on 111 and 190 transplant patients found a very 
similar proportion with hypersensitivity myocarditis (8 cases, 7.2% and 14 cases, 7.4%) in explanted 
hearts153, 154. Of these, 4/8 (50%) and 12/14 (86%) had eosinophilia before transplantation. Most pre- and 
post-transplant characteristics were similar between patients with and without hypersensitivity myocarditis 
and there was no difference in post-transplant survival in patients with or without eosinophilic myocarditis. 
None of the 14 patients showed recurrent eosinophilic myocarditis on post-transplant biopsies154. Multiple 
drug therapy, and specifically inotropic support was suspected to have caused the hypersensitivity reaction 
leading to eosinophilic myocarditis. The most recent and largest study on 759 heart transplant patients 
showed a lower rate of eosinophilic myocarditis with only 21 cases (2.7%)155. The authors noted a potential 
trend to decreasing hypersensitivity myocarditis from 2000 to 2010. Again, none of the cases were 
diagnosed clinically and post-transplant survival was similar in those with and without eosinophilic 
myocarditis. There was, however, increased acute cellular reaction in the transplanted hearts of those 
patients with hypersensitivity myocarditis in the explanted heart compared to other transplants. About 
4,000 to 5,000 heart transplantations are performed annually worldwide, with the vast majority taking 
place in North America and Europe157. At a rate of 2.7% to 7.4% of hypersensitivity myocarditis, an 
estimated 108-370 cases of hypersensitivity myocarditis in patients awaiting heart transplantation likely 
occur worldwide per year.  
Tropical endomyocardial fibrosis 
Tropical endomyocardial fibrosis is a form of eosinophilic endomyocarditis that is concentrated in Sub-
Saharan Africa, particularly Uganda, Kenya, Tanzania, Mozambique, Gabon, Congo, Cameroon, Sudan, 
Nigeria, Cote d’Ivoire and Ghana158. In addition, it can be found in parts of South America and Asia38. The 
etiology of endomyocardial fibrosis is not known. One hypothesis is that helminth-induced chronic 
eosinophilia leads to endomyocardial fibrosis in a process similar to that in patients with hypereosinophilic 
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syndrome159. Others believe that there is a toxic cause160. In endemic regions, tropical endomyocardial 
fibrosis may account for a large proportion of heart disease (20% of cases referred for echocardiography in 
a study in Uganda)161 and the disease is most frequent in children and young adults158. Mortality is very high 
with 25% survival by 2 years in a study from the 1970s162. More recent estimates suggest that tropical 
endomyocardial fibrosis may account for 1% of heart failure in Sub-Saharan Africa102. Eosinophilia has been 
reported as a risk factor in Uganda and Nigeria, and duration of disease is inversely correlated with 
eosinophilia158, suggesting that eosinophils may be involved in the initiation or early stages of disease. 
Eosinophilic granulomatosis with polyangiitis 
Eosinophilic granulomatosis with polyangiitis (EGPA) is one of the rarest systemic necrotizing vasculitides. 
The incidence is estimated to be approximately 0.11 to 2.66 cases per 1,000,000 person-years and the 
prevalence is about 10.7 to 14 per 1 million adults163. A total of 383 patients have been enrolled in the 
French Vasculitis Study Group cohort since 198332. Among these patients, the 5-year survival rate is 90%. 
For patients with cardiac involvement, the 5-year survival rate is substantially lower at 78%. Eosinophilic 
myocarditis develops in about one third of EGPA patients164. While EGPA is an extremely rare disease, a 
large proportion of patients (one third) develops eosinophilic myocarditis, which contributes to mortality. 
Hypereosinophilic syndrome 
Hypereosinophilic syndrome is a rare and complex disease defined by prolonged hypereosinophilia (> 1500 
/µl blood) and organ damage in the absence of other primary causes35. The largest report on HES patients 
was a multicenter study from 11 institutions in the U.S. and Europe with 188 patients165. Cardiac 
manifestations of HES include necrotizing myocarditis, mural thrombus formation and fibrosis, particularly 
of the endocardium166. These occur in 5%-58% of HES patients35. The survival rate for patients with HES is 
not clear, but cardiac manifestations are thought to be the major contributor to morbidity and mortality33.  
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Giant cell myocarditis 
Giant cell myocarditis is the rarest form of myocarditis118. The diagnosis requires endomyocardial biopsies 
with myocyte injury with or without necrosis167. The key characteristic is the presence of multinucleated 
giant cells forming part of the inflammatory infiltrate with lymphocytes and eosinophils. As eosinophils are 
almost always a dominant feature of giant cell myocarditis, this disease is briefly discussed here. About one 
third of patients has moderate eosinophil infiltration167. Giant cell myocarditis is thought to be autoimmune 
in nature; 17-19% of patients suffer from additional non-cardiac autoimmune diseases167-169. For Finnland, 
the incidence rate of giant cell myocarditis was estimated as 0.67 per 100,000 person-years in the adult (> 
18 years of age) population167. No other data on the incidence of this type of myocarditis exist. However, 
the frequency of giant cell myocarditis in autopsies was evaluated in India. Autopsy records from a tertiary 
referral center revealed 12 cases of giant cell myocarditis (0.005% of autopsies, 0.8% of myocarditis cases) 
between 1994 to 2010 170. Giant cell myocarditis is thought to be the most severe form of myocarditis, 
frequently resulting in death or heart transplantation. In an earlier study, the median survival was 5.5 
months from the onset of symptoms. More recently, median survival was reported to be around 5 years167, 
171. Strong immunosuppressive treatment may improve survival169, 171. Whether eosinophils contribute to 
mortality in giant cell myocarditis remains to be determined. 
In summary, eosinophilic myocarditis is a relatively rare form of myocarditis, accounting for about 2-22% of 
myocarditis patients. Eosinophilic myocarditis is more frequently found in certain groups, such as EGPA or 
HES patients and those awaiting heart transplantations. In addition, eosinophilic myocarditis can occur as 
a rare complication in patients with parasitic infections or as part of a hypersensitivity reaction to drugs.   
Dilated cardiomyopathy 
DCM is defined as left ventricular or biventricular systolic dysfunction (abnormal ejection fraction) and 
dilation (> 2 standard deviations from normal) that are not explained by abnormal loading conditions or 
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coronary artery disease47. The incidence rate for DCM in adults is about 5-8 / 100,000 person-years and the 
prevalence is 36-40 / 100,000 adults172. DCM studies report a female/male ratio between 1:1.3 and 1:1.5122. 
DCM is the major cause of heart failure in patients under 40 years of age. The 5-year survival rate is less 
than 50%173. About 9-16% of patients with new onset DCM have evidence of prior myocarditis48-50. 
Myocarditis as a cause of DCM was associated with poor survival post transplantation174. 
Dilated cardiomyopathy in children 
In children, DCM is the most common cardiomyopathy and the leading indication for heart 
transplantation175. The presenting symptom of DCM in children is often heart failure176. The incidence of 
pediatric DCM is 0.57-0.76 / 100,000 person-years139, 177, 178 and is higher in younger children compared to 
older children139. Myocarditis may cause a higher proportion of DCM in children than in adults. Myocarditis 
was identified as the cause of DCM in 16% of pediatric patients in one study176 and in 40% of patients 
biopsied within 2 months of diagnosis in another study139. Recovery of heart function in children with DCM 
is possible, but a large proportion will experience death or require heart transplantation. By one year of 
follow-up, 29-34% of pediatric DCM patients experience either death or heart transplantation112, 178. 
Another study found that by 2 years of follow-up, 22% had recovered LV function and size, 51% had 
experience death or heart transplantation and 27% lived with persistent functional deficiencies179.  Longer 
follow-up studies show that there is an ongoing risk of death. About 40% of children with DCM due to 
myocarditis and almost 60% of children with idiopathic DCM experienced transplantation or death at 10 
years of follow-up109, 112. The cost of pediatric heart failure is not entirely known, but the average hospital 
charge for hospitalization due to heart failure in the US was over US$ 70,000 in 2009180. DCM may 
disproportionally affect children in disadvantaged populations. In a study conducted in Australia, 
indigenous Australian children had an increased risk of DCM (relative risk 2.67, 95% confidence interval: 
1.42–4.63) and a higher rate of death as presenting symptom139. The authors suggest that this may be a 
result of decreased availability of health care.  
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DCM is a major cause of heart failure in children and young adults and carries a dire prognosis. Myocarditis 
accounts for 10-40% of DCM cases and the frequency is likely higher in children than in adults. It is not 
entirely clear if DCM due to myocarditis carries a more or less favorable outcome compared to other types 
of DCM.  
Conclusions 
Large gaps remain in our understanding of the burden of myocarditis. To date, there are no reliable 
estimates of the incidence or prevalence of myocarditis. Comparisons of regional differences in incidence, 
etiology, or risk factors are therefore not possible. However, it seems clear that men are at a higher risk of 
myocarditis than women. Moreover, we have a good understanding of the natural history of myocarditis. 
About 60% of myocarditis patients may recover, about 15-20% go on to develop DCM, and the remaining 
20-25% will either require a heart transplant or die. Most studies on myocarditis and DCM come from North 
America, Western Europe, Japan, and Australia. It is possible that there are large differences in the 
epidemiology of myocarditis and DCM in different regions. For example, it has been suggested that 
cardiomyopathies are endemic in Sub-Saharan Africa181. Myocarditis likely cause 10-40% of DCM cases. 
DCM in turn is the major indication for heart transplantations in children and young adults and a major 
cause of heart failure. Thus, myocarditis contributes significantly to the burden of heart failure. Our 
knowledge on the myocarditis subtype of eosinophilic myocarditis is even more limited. No reliable data 
exist on the incidence / prevalence, natural history, or outcomes of eosinophilic myocarditis. Nevertheless, 
eosinophilic myocarditis contributes significantly to morbidity and mortality in patients with EGPA and HES, 
is frequently found in patients awaiting heart transplantation, and is a rare, but potentially fatal 
complication of commonly used drugs and common infectious diseases. More research is required to begin 




Chapter 3: Eosinophil trafficking to the heart in eosinophilic myocarditis 
This chapter was published in the European Journal of Immunology74: 
Diny NL, Hou X, Barin JG, Chen G, Talor MV, Schaub J, Russell SD, Klingel K, Rose NR, Čiháková D. 
Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking 
to the heart. Eur J Immunol. 2016 Dec;46(12):2749-2760. (Copyright Wiley-VCH Verlag GmbH & Co. KGaA. 
Reproduced with permission.) 
Summary 
Cardiac manifestations are a major cause of morbidity and mortality in patients with eosinophil-associated 
diseases. Eosinophils are thought to play a pathogenic role in the heart. We investigated the pathways that 
recruit eosinophils to the heart using a model of eosinophilic myocarditis where experimental autoimmune 
myocarditis is induced in IFNγ-/-IL-17A-/- mice. Two conditions have to be met for efficient eosinophil 
trafficking to the heart: high eotaxin (CCL11, CCL24) expression in the heart and expression of the eotaxin 
receptor CCR3 by eosinophils. We identified the source of CCL11 as cardiac fibroblasts with interstitial 
localization in the heart. CCL24 is produced by F4/80+ macrophages localized at inflammatory foci. 
Expression of these chemokines is controlled by Th2 cytokines, IL-4 and IL-13. To determine the relevance 
of this pathway in humans, we analyzed endomyocardial biopsy samples from myocarditis patients. 
Expression of CCL11 and CCL26 was significantly increased in eosinophilic myocarditis compared to chronic 
lymphocytic myocarditis and positively correlated with the number of eosinophils. Thus, eosinophil 
trafficking to the heart is dependent on the eotaxin-CCR3 pathway in a mouse model and associated with 




Cardiac manifestations are a major cause of morbidity and mortality in patients with eosinophilia. In 
hypereosinophilic syndrome (HES), 20-50% of patients develop fibrosis or inflammation of the 
endocardium, myocardium, or pericardium33, 34, 182. Similarly, one third of patients with eosinophilic 
granulomatosis with polyangiitis (EGPA) suffer from cardiovascular manifestations32, 35. Eosinophilic 
myocarditis can also develop in the absence of prolonged peripheral eosinophilia, for example, in the 
potentially fatal form of acute necrotizing eosinophilic myocarditis, in patients with parasitic diseases, or as 
hypersensitivity myocarditis in response to drugs14, 24. No specific biomarkers or treatments are currently 
available for eosinophilic myocarditis; patients usually receive immunosuppressive therapy and 
symptomatic treatment in later stages13, 24, 183. A recent report from the NIH taskforce on the Research 
Needs of Eosinophil-Associated Diseases underscored the need for animal models to study organ-targeted 
eosinophil accumulation184. 
Given the strong association of eosinophils with cardiac disease, eosinophils are believed to play a 
pathogenic role in the heart40, 185. Eosinophils may be directly cytotoxic to cardiomyocytes39, 43, 44, activate 
cardiac mast cells45, or release pro-thrombotic tissue factor46. Eosinophil granule proteins are deposited in 
the myocardium during eosinophilic myocarditis186. They are thought to damage the endocardium, resulting 
in thrombosis and endocarditis, and eventually in endomyocardial fibrosis and valvular complications33, 182. 
Animal studies further strengthen the evidence that eosinophils contribute to pathology and mortality in 
eosinophilic myocarditis187, 188 189. 
Despite the clear link between eosinophils and cardiac damage, the pathways that recruit eosinophils to 
the heart have not been described. Eosinophils develop in the bone marrow and are released into the blood 
in response to IL-5. From there, they migrate into tissues66. Eosinophils express numerous receptors for 
chemokines and other mediators that can direct trafficking190. The eotaxins are the strongest eosinophil 
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attracting chemokines191 and the most studied69, 71, 72, 192. Whether eotaxins play a role in eosinophil 
trafficking to the heart, however, is not known.  
To discover the signals responsible for eosinophil trafficking to the heart, we used a mouse model of 
eosinophilic myocarditis previously established by our group189. Induction of experimental autoimmune 
myocarditis (EAM) in mice lacking the key Th1 and Th17 cytokines IFNγ and IL-17A results in a fatal, Th2-
driven form of myocarditis that is characterized by a predominantly eosinophilic infiltrate. We identified 
the signaling pathway controlling eosinophil trafficking to the inflamed heart and the cell types producing 
the required chemoattractants. We then validated our findings in patients with eosinophilic myocarditis. 
Methods 
Patients 
Endomyocardial biopsies were taken at multiple centers for routine diagnostic purposes to evaluate the 
pathologic basis of unspecified congestive heart failure. Samples were investigated in the Department of 
Molecular Pathology at the University Hospital of Tübingen, Germany by histology, immunohistochemistry 
and molecular pathology to identify infectious agents in the myocardium as described193. Written informed 
consent for further examination was obtained from all patients. We analyzed remaining de-identified tissue 
from 14 patients with chronic lymphocytic myocarditis and 16 patients with eosinophilic myocarditis. 
Diagnosis of myocarditis was based on established criteria2 and all samples were negative for viral 
infections. Patient age and gender are summarized in Table 6. 
Table 6: Patient characteristics 
Characteristic Chronic myocarditis (n=14) Eosinophilic myocarditis (n=16) P value 
Age in years (median, range) 54, 42-79 53.5, 29-82 0.557* 
Female sex (n, %) 3, 21.4% 10, 62.5% 0.024† 
* t-test 





Wildtype (WT, JAX 0651), ΔdblGATA1 (JAX 5653194), IFNγ-/- (JAX 2286), and CCR3-/- mice (JAX 5440), all on 
the BALB/c background, were obtained from Jackson Laboratories (Bar Harbor, ME). IL-5 transgenic (IL-5Tg) 
founder mice195 were kindly provided by James Lee and Nancy Lee (Mayo Clinic Arizona, Scottsdale, AZ). IL-
17A-/- founder mice were generously provided by Yoichiro Iwakura (University of Tokyo, Tokyo, Japan). IFNγ-
/- mice were crossed with IL-17A-/- mice and bred to homozygosity. Resulting IFNγ-/-IL-17A-/- mice were then 
crossed with ΔdblGATA1 mice or with CCR3-/- mice and offspring were intercrossed to generate mice 
homozygous at all loci. All mice were maintained at the Johns Hopkins University School of Medicine specific 
pathogen-free animal vivarium. The number of animals used in each experiment and the number of repeats 
are listed in the figure legends. Experiments were performed in accordance with the guidelines set forth in 
the Guide for the Care and Use of Laboratory Animals196. All methods and protocols were approved by the 
Animal Care and Use Committee of the Johns Hopkins University. 
Experimental autoimmune myocarditis 
To induce myocarditis, male mice age 6-9 weeks were immunized on days 0 and 7 with 100 µg MyHCα614-
629 peptide emulsified in Complete Freund’s Adjuvant (Sigma-Aldrich) supplemented to 5 mg/ml with heat-
killed Mycobacterium tuberculosis strain H37Ra (Difco). Mice were also administered 500 ng pertussis toxin 
(List Biologicals) ip on day 0. 
Eosinophil isolation 
Blood from female IL-5Tg and CCR3-/-IL-5Tg donors was collected into phosphate buffered saline (PBS) with 
100 U/ml Heparin, layered over Histopaque-1119 (Sigma-Aldrich), and centrifuged. Interphase cells were 
collected and washed in PBS. Red blood cells were lysed with ACK buffer (Quality Biologicals). Eosinophils 
were enriched by negative MACS selection with anti-CD90.2 and anti-CD45R beads (Miltenyi Biotech). 
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Eosinophil purity was determined by flow cytometry staining for CD11b, Ly6G, Ly6C, and SiglecF and ranged 
from 87% to 93%. 
Flow cytometry and cell sorting 
Hearts were perfused through the ventricles with PBS for 3 min. Single-cell suspensions were generated 
from heart tissue by digestion with Collagenase II and DNase I (Worthington) in HBSS in GentleMACS C 
Tubes according to manufacturer’s instructions (Miltenyi Biotech). Splenocytes were isolated into single-
cell suspension, and bone marrow cells were collected from femurs followed by red blood cell lysis with 
ACK buffer. Intestinal lamina propria cells were isolated from the distal 5 cm of the small intestine. 
Intestines were flushed, cut into <1 cm pieces, and incubated twice in HBSS, 5% fetal bovine serum (FBS), 
5mM EDTA, 10mM HEPES, and Penicillin/Streptomycin for 20 min at 37°C. Supernatants were discarded 
between incubations. Tissues were incubated for 60 min at 37°C in HBSS with Ca2+ and Mg2+, 10mM HEPES, 
5% FBS, 1 mg/ml collagenase D, 0.1 mg/ml DNase I, and 3 mg/ml Dispase II (Roche). Using GentleMACS C 
Tubes, cells were mechanically separated according to manufacturer’s instructions (Miltenyi Biotech). 
Following filtration through 70µm filters, single-cell suspensions were stained with LIVE/DEAD stain 
(Molecular Probes), washed, FcγRII/III blocked with a-CD16/CD32, and stained with fluorochrome-
conjugated antibodies (eBioscience, BioLegend, BD Pharmingen). For detection of Ccl11 mRNA, samples 
were processed using the FlowRNA II Assay kit (Affymetrix eBioscience) according to manufacturer’s 
protocols. In brief, samples were stained with fluorochrome-conjugated antibodies against surface 
antigens, fixed and permeabilized, and hybridized with a type 1 Ccl11 probe or Actb control probe. Signal 
amplification was achieved through a branched DNA structure, which was then hybridized to a probe 
conjugated to Alexa Fluor647. Samples were acquired on a LSRII 4-laser cytometer running FACSDiva 6.0 
(BD Immunocytometry) and analyzed using FlowJo 10.0.8 (TreeStar Software). For cell sorting, single cell 
suspensions were layered over a Histopaque-1119 gradient, stained, and sorted on an AriaIIu cell sorter. 
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Cardiac fibroblast isolation and culture 
Primary adult mouse cardiac fibroblasts were isolated as described197. Hearts were cannulated through the 
aorta and perfused for 3 min at 37°C and 4 ml/min with perfusion buffer: 7.03g/L NaCl, 1.1 g/L KCl, 0.082 
g/L KH2PO4, 0.085 g/L Na2HPO4, 0.144 g/L MgSO4, 2.38 g/L HEPES, 0.39 g/L NaHCO3, 1 g/L glucose, 3.74 g/L 
Taurine, 2 g/L 2,3-Butanedione monoxime (all Sigma). Next, hearts were perfused for 4 min with perfusion 
buffer supplemented with 12 g/L Collagenase II (Worthington) and 0.5 g/L Protease XIV (Sigma-Aldrich), 
and for 8 min with addition of digestion enzymes and 0.03M CaCl2. Hearts were cut into small pieces and 
cells separated by repeated pipetting for 3 min. Cells were filtered through a 70 µm filter and washed in 
DMEM (Gibco). Cells were plated in DMEM with 20% FBS (GE Healthcare Life Sciences), nonessential amino 
acids (Sigma), Penicillin/Streptomycin, 2mM L-Glutamine, and 25mM HEPES (all Quality Biological). Non-
adherent cells were washed away after 1h. Fibroblasts of passage 2-3 were used in experiments. Cells and 
supernatants were harvested at the indicated time points after addition of recombinant mouse cytokines 
(R&D Systems). 
Bone marrow-derived macrophage culture 
Bone marrow was isolated from adult WT male mice, red blood cells lysed with ACK buffer, and cells 
cultured in complete DMEM as above with 20 ng/ml recombinant mouse M-CSF and 10 ng/ml GM-CSF (R&D 
Systems) for 10 days. Media was replaced on days 3 and 6. On day 10, cells were seeded in media without 
M-CSF or GM-CSF. Cells and supernatants were harvested 24h after stimulation with cytokines on day 11 
(R&D Systems). 
Quantitative Real-time PCR 
Mouse tissue and cell mRNA was extracted in TRIzol (Invitrogen), quantitated by spectrophotometry, 
reverse transcribed (High-Capacity cDNA Reverse Transcription Kit, Applied Biosystems), and amplified with 
Power SYBR Green PCR Master Mix (Bio-Rad) on a MyiQ2 thermocycler running iQ5 software (Bio-Rad). 
Primers for mouse genes (Gapdh: 5’-TCCTCCTCAGACCGCTTTT-3’ and 5’-TCTGCTGGAGTCCCCTTG-3’, 
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Ccl11: 5’-GAATCACCAACAACAGATGCAC-3’ and 5’-TCCTGGACCCACTTCTTCTT-3’, Ccl24: 5’-
TCTTAGGGCCCTTCTTGGTG-3’ and 5’-AATTCCAGAAAACCGAGTGG-3’) were commercially synthesized 
(Integrated DNA Technologies). Data were analyzed using the 2-ΔΔCt method198 by normalizing threshold 
cycles to Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and controls. RNA from endomyocardial 
biopsies was isolated using the PureLink FFPE RNA Isolation Kit (Invitrogen) from three to five 5-µm-thick 
sections per sample, reverse transcribed, and amplified using the iTaq Universal Probes Supermix (Bio-Rad) 
with TaqMan Gene Expression Assay (Applied Biosystems) for HPRT, CCL11, CCL24, and CCL26. Data were 
analyzed by normalizing threshold cycles to HPRT. 
ELISA 
Cell culture supernatants were assayed for CCL11 using the Mouse CCL11/Eotaxin Quantikine ELISA Kit (R&D 
systems) and for CCL24 using the Eotaxin-2 (CCL24) Mouse ELISA Kit (Abcam) according to manufacturer’s 
instructions. 
Histology and immunohistochemistry 
Mouse hearts were cut in half, fixed in SafeFix (Thermo Fisher Scientific), paraffin embedded, and cut into 
5-µm-thick sections (Histoserv). Serial sections were stained with 5 µg/ml polyclonal goat anti-mouse CCL11 
or CCL24 antibodies (R&D Systems) using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (R&D Systems) 
according to manufacturer’s protocol and counterstained with Hematoxylin. The number of infiltrating 
eosinophils was determined by counting eosinophils on 40X images of H&E-stained biopsy sections. The 
number of eosinophils was averaged over the area observed. 
Statistics 
Two groups were analyzed using Student’s t-test for normally distributed data or Mann-Whitney test for 
nonparametric data. Multiple group analysis was performed by one-way ANOVA followed by Tukey’s 
multiple comparisons test or Dunnett’s multiple comparisons test. Calculations were performed in Prism 6 
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(GraphPad Software Inc.). p values <0.05 were considered statistically significant and are denoted by 
asterisks: *p<0.05, **p<0.01, ***p<0.001. 
Results 
Eosinophils localize to the heart in response to eotaxin-CCR3 signaling 
We hypothesized that the eotaxin-CCR3 pathway is important for eosinophil trafficking to the heart based 
on our previous observations that Ccl11 (eotaxin-1) and Ccl24 (eotaxin-2) expression are substantially 
increased in IFNγ-/-IL-17A-/- mice with eosinophilic myocarditis compared to WT mice during EAM189. By 
including additional groups, we determined that this expression pattern also occurs in the absence of 
eosinophils in ΔdblGATA1 and IFNγ-/-IL-17A-/-ΔdblGATA1 mice (Figure 6A). IFNγ-/-IL-17A-/-ΔdblGATA1 mice 
showed substantially higher cardiac expression of Ccl11 and Ccl24 than ΔdblGATA1 mice at day 21 of EAM. 
This finding establishes that eosinophils are not required for eotaxin expression in the heart during EAM. 
We employed adoptive cell transfer to determine the importance of the eotaxin receptor CCR3 in eosinophil 
trafficking to the heart (Figure 6B). Eosinophils were isolated from IL-5 transgenic mice (IL-5Tg) because 
these mice develop massive eosinophilia195. Recipient ΔdblGATA1 and IFNγ-/-IL-17A-/-ΔdblGATA1 mice 
deficient in eosinophils were immunized on days 0 and 7 to induce EAM. On day 20, eosinophils were 
isolated from peripheral blood of IL-5TgCCR3+/+ and IL-5TgCCR3-/- donor mice and 107 donor cells were 
injected intravenously into recipients. The following day, recipients were sacrificed. Eosinophil infiltration 
in multiple organs was quantified by flow cytometry (Figure 6C-E, Figure 7A-B). All eosinophils recovered in 
the recipients were necessarily donor-derived because the ΔdblGATA1 mutation blocks eosinophil 
development in the bone marrow194. Only when CCR3-expressing eosinophils were injected into IFNγ-/-IL-
17A-/-ΔdblGATA1 recipients, could significant numbers of eosinophils be retrieved from the heart (Figure 
6C, D). This combination of donor and recipient alone resulted in a significant increase in cardiac eosinophils 
in both frequency (Figure 6C, E) and absolute numbers (Figure 6D). Use of bone marrow-derived eosinophils 
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from WT and CCR3-/- donors for adoptive transfer yielded the same results (data not shown). Expression of 
CCR3 by eosinophils allowed for substantial eosinophil trafficking to the heart, but only in the presence of 
high cardiac eotaxin expression. Therefore, two conditions are required for efficient eosinophil trafficking 
to the heart: substantial eotaxin expression in the heart as in the IFNγ-/-IL-17A-/-ΔdblGATA1 mice and 
expression of the CCR3 receptor on eosinophils. These data led us to conclude that the CCR3-eotaxin 
pathway is essential for eosinophil trafficking to the heart.  
Eosinophils reach highest frequency in the hearts of IFNγ-/-IL-17A-/-ΔdblGATA1 mice 
To determine whether eosinophil migration into tissues in response to the eotaxin-CCR3 pathway was intact 
in ΔdblGATA1 recipients, we analyzed eosinophil numbers in the small intestine in parallel with the heart. 
The intestine harbors eosinophils under steady-state conditions in mice and humans192, 199. Eosinophil 
trafficking to the intestine is known to be dependent on the eotaxin-CCR3 pathway69. CCR3-expressing 
eosinophils were found at significantly higher frequencies in the intestines of both recipients compared to 
CCR3-deficient eosinophils (Figure 1E). Adoptively transferred eosinophils were also retrieved from 
peripheral blood, spleen, and bone marrow at low frequencies (Figure 6E, Figure 8, Figure 7B). A role for 
the eotaxin-CCR3 pathway has not been described for these organs, and we did not find more CCR3+/+ 
eosinophils compared to CCR3-/- eosinophils in any of these tissues (Figure 6E, Figure 7B).   
Importantly, transferred CCR3+/+ eosinophils in IFNγ-/-IL-17A-/-ΔdblGATA1 recipients reached higher 
frequencies in the heart than any other organ (Figure 8A). Eosinophil frequency in the heart was about 10- 
to 20-fold higher than in the blood or spleen and about 2-fold higher than in the intestine. In contrast, in 
ΔdblGATA1 recipients transferred CCR3+/+ eosinophils were increased in the small intestine compared to all 
other organs, including the heart (Figure 8B). Thus, eosinophils are specifically recruited to the heart by the 





Figure 6: CCR3 is required for eosinophil trafficking to the heart in eosinophilic myocarditis  
A) Expression of indicated genes was analyzed by qPCR from heart homogenates at day 21 post-
immunization and is expressed as 2-ΔΔCt values relative to Gapdh and naïve WT mice. B) Schematic of 
adoptive eosinophil transfer into immunized recipient mice for data depicted in (C-D). C) Representative 
bivariate flow cytometry plots showing SiglecF+Ly6Glo eosinophils as a proportion of viable CD45+ heart-
infiltrating cells following transfer. D) Total number of heart-infiltrating eosinophils after eosinophil 
transfer. E) Frequency of eosinophils in different organs following adoptive transfer. Groups were compared 
by one-way ANOVA followed by Tukey’s multiple comparison. Data points represent individual animals, 






Figure 7: Gating strategy of eosinophils  
Eosinophil frequency in indicated organs one day following adoptive transfer of CCR3+/+ eosinophils into 
IFNγ-/-IL-17A-/-ΔdblGATA1 recipients (A) and ΔdblGATA1 recipients (B). The same experiment as in Figure 1E 
is shown. Groups were compared by one-way ANOVA followed by Tukey’s multiple comparison. Data points 
represent individual animals, bars indicate means. Data are representative of 2 independent experiments. 







Figure 8: Adoptively transferred eosinophils reach highest frequency in the heart 
Eosinophil frequency in indicated organs one day following adoptive transfer of CCR3+/+ eosinophils into 
IFNγ-/-IL-17A-/-ΔdblGATA1 recipients (A) and ΔdblGATA1 recipients (B). The same experiment as in Figure 6E 
is shown. Groups were compared by one-way ANOVA followed by Tukey’s multiple comparison. Data points 
represent individual animals, bars indicate means. Data are representative of 2 independent experiments. 




Genetic ablation of CCR3 in IFNγ-/-IL-17A-/- mice blocks eosinophil trafficking to the heart 
To further test our hypothesis that eosinophil trafficking to the heart is mainly CCR3-dependent in 
eosinophilic myocarditis, we crossed IFNγ-/-IL-17A-/- mice with CCR3-/-mice. Eosinophil frequencies in the 
heart were dramatically reduced from 24% in IFNγ-/-IL-17A-/- mice to 2% in IFNγ-/-IL-17A-/-CCR3-/- mice on 
day 21 of EAM (Figure 9A, B). Eosinophil frequencies in the spleens did not differ between the two strains 
(Figure 9C). Although considerably diminished, eosinophils were not entirely absent from the hearts of IFNγ-
/-IL-17A-/-CCR3-/- mice (Figure 9A, B) and accounted for similar frequencies in heart and spleen on day 21 of 
EAM (Figure 9B, C). This suggests that there is no specific recruitment of eosinophils to the heart in the 
absence of CCR3.  
Expression of CCR3 has also been reported on human Th2 cells79. We observed similar CD4+ T cell 
frequencies in the presence or absence of CCR3 during EAM (Figure 9D). This indicates that reduced 
eosinophil trafficking to the heart in IFNγ-/-IL-17A-/-CCR3-/- mice is not a consequence of decreased T cell 
infiltration. Moreover, all 3 strains developed myocarditis of similar histopathologic severity (data not 
shown). Taken together, these findings demonstrate that in eosinophilic myocarditis without peripheral 
eosinophilia, as is observed in IFNγ-/-IL-17A-/- mice, eosinophil trafficking to the heart is dependent on the 
eotaxin-CCR3 pathway.  
CCL11 and CCL24 are expressed by different cell types in the heart 
Immunohistochemical staining for eotaxins on serial heart sections revealed interstitial expression of CCL11 
at day 21 of EAM in IFNγ-/-IL-17A-/-ΔdblGATA1 mice (Figure 10A), ΔdblGATA1 mice (Figure 10E), and naïve 
mice of both strains (data not shown). Only single CCL11+ cells were observed in inflammatory foci (Figure 
10B, F). This pattern is consistent with expression by fibroblasts. CCL24, in contrast, was not detected 
interstitially between cardiomyocytes (Figure 10C, G). Instead, CCL24 localized to areas of inflammation in 
IFNγ-/-IL-17A-/-ΔdblGATA1 mice (Figure 10D), consistent with expression by heart infiltrating cells. CCL24 
was not detectable in ΔdblGATA1 mice (Figure 10G, H) or naïve mouse hearts of either genotype (data not 
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shown). This demonstrates that CCL11 and CCL24 are expressed by different cell types in the heart and 
under different conditions. 
 
 
Figure 9: Genetic ablation of CCR3 in IFNγ-/-IL-17A-/- mice reduces eosinophil frequency in the heart 
A) Representative bivariate flow cytometry plots of heart-infiltrating CD45+ cells. Gates show frequency of 
SiglecF+SSChi eosinophils. B-D) Eosinophil and T helper cell frequency in heart and spleen at day 21 post-
immunization in the indicated strains. Groups were compared by one-way ANOVA followed by Tukey’s 
multiple comparison. Data points represent individual animals, bars indicate means. Data are 




Cardiac fibroblasts are major CCL11 producers in the heart 
Next, we sought to establish which cell types specifically were responsible for eotaxin production. We used 
a Ccl11 mRNA probe for flow cytometry to address this question in an unbiased manner. We included 
surface markers for the identification of tissue resident cells and infiltrating hematopoietic-lineage cells 
(Figure 11). Out of the different cell populations in the heart at day 21 of EAM, the highest expression of 
Ccl11 was detected in CD45-CD31-CD140a+ cardiac fibroblasts (Figure 10I, J). This fibroblast subset showed 
significantly higher Ccl11 expression compared to total viable cells for both IFNγ-/-IL-17A-/-ΔdblGATA1 and 
ΔdblGATA1 mice (Figure 10J). Low levels of Ccl11 expression could be detected by qPCR even in naïve 
hearts. The highest Ccl11 signal in naïve heart cells was also in the CD140a+ fibroblast subset (data not 
shown). Thus, cardiac fibroblasts are the major producer of Ccl11 in the heart during steady-state and in 
myocarditis. To confirm these results with an independent method, we sorted several cell populations from 
ΔdblGATA1 and IFNγ-/-IL-17A-/-ΔdblGATA1 mice at day 21 of EAM and analyzed eotaxin expression by qPCR. 
CD31+ endothelial cells were depleted before cells were sorted by FACS (Figure 12A). Again, CD45-CD140a+ 
fibroblasts showed the highest expression of Ccl11 compared to all other sorted cells (Figure 10K). In 
conclusion, the major producers of CCL11 are CD140a+ cardiac fibroblasts located interstitially between 
myocytes. These CCL11-expressing fibroblasts were found in both ΔdblGATA1 and IFNγ-/-IL-17A-/-
ΔdblGATA1 mice at steady-state and in EAM. 
CCL24 is produced by F4/80+ macrophages during myocarditis 
Unlike Ccl11, which was upregulated 4-fold during EAM in ΔdblGATA1 compared to naïve mice, Ccl24 did 
not increase in EAM in ΔdblGATA1 mice (Figure 12B). In the IFNγ-/-IL-17A-/-ΔdblGATA1 mice, however, Ccl24 
was highly upregulated during EAM (Figure 10L, Figure 12B). The populations shown in Figure 10K did not 
conclusively reveal the major Ccl24 expressing cell type (Figure 12B). Therefore, we sorted 10 overlapping 
populations (Figure 13) and assayed them for Ccl24 expression. CD45+CD11b+Ly6G-F4/80+ macrophages 
were the major Ccl24 expressing cells in EAM in IFNγ-/-IL-17A-/-ΔdblGATA1 mice (Figure 10L). Expression of 
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CCL24 by macrophages is consistent with localization to inflammatory foci observed by 
immunohistochemistry (Figure 10). The staining for eotaxin proteins on serial sections (Figure 10A-H) and 
qPCR from different sorted cell populations (Figure 10K, L, Figure 14) clearly demonstrated that CCL11 and 
CCL24 were expressed by different cell types during EAM. CCL24 was produced by F4/80+ macrophages, 






Figure 10: CCL11 is expressed by cardiac fibroblasts while CCL24 is expressed by F4/80+ macrophages 
during eosinophilic myocarditis 
A-H) Immunohistochemistry staining for CCL11 (A-B, E-F) and CCL24 (C-D, G-H) of heart sections from day 
21 in IFNγ-/-IL-17A-/-ΔdblGATA1 mice (A-D) and ΔdblGATA1 mice (E-H) showing areas without (A, C, E, G) 
and with inflammation (B, D, F, H). Pictures are representative of 2-3 mice per group. Black scale bars: 20 
µm, red scale bars: 5 µm. I) Ccl11 expression was detected using a probe against Ccl11 mRNA in the 
FlowRNA II Assay and is shown for total viable cells (blue) and CD140a+ fibroblasts (red) at day 21 post-
immunization from concatenated samples from 5-6 mice per group. J) Mean fluorescence intensity (MFI) 
for Ccl11 probe in total viable cells and indicated cell populations. Mean ± SD of 5-6 mice per group. K) Ccl11 
expression in cells sorted from 3 individual mice per group as in Supplemental Figure 3. L) Ccl24 expression 
in cells sorted from 4 individual mice as in Supplemental Figure 4. K, L) Eotaxin expression was analyzed by 
qPCR and normalized to Gapdh and naïve mouse heart homogenates, shown is mean ± SD. Gene expression 
in heart homogenates from naïve and immunized mice are included for comparison. J-L) Groups were 
compared by one-way ANOVA followed by Dunnett’s multiple comparison test comparing all subsets to 









Figure 11: Gating strategy for prime flow RNA assay  
Gating strategy is shown representatively for an IFNγ-/-IL-17A-/-ΔdblGATA1 mouse. Mean fluorescence 
intensity for the Ccl11 probe in Figure 4J was determined for each cell population starting with total viable 




Figure 12: Flow sorting of cardiac resident and cardiac infiltrating cells  
A) Gating strategy is shown representatively for an IFNγ-/-IL-17A-/-ΔdblGATA1 mouse. Cells were isolated 
from hearts at day 21 of EAM, first depleted of endothelial cells using anti-CD31 beads and then sorted into 
4 populations:  CD45-Cd140a-, CD45-CD140a+, CD45+CX3CR1+Ly6G-, CD45+CX3CR1-Ly6G-. B), Ccl24 
expression in sorted cells and whole heart homogenates was analyzed by qPCR and normalized to Gapdh 
and naïve heart homogenates. Cells were sorted from 3 individual mice, shown is mean ± SD. Groups were 
compared by one-way ANOVA followed by Dunnett’s multiple comparison comparing all subsets to naïve 








Figure 13: Gating strategy for flow sorting of heart infiltrating and resident cell populations  
Gating strategy is shown representatively for an IFNγ-/-IL-17A-/-ΔdblGATA1 mouse. A total of 10 overlapping 
populations were sorted: CD45-, CD45-CD31-, CD45-CD31+, CD45+, CD45+CD90+CD11b-, CD45+CD90-CD11b-, 





Figure 14: Ccl11 expression in sorted cells  
Cells were sorted from IFNγ-/-IL-17A-/-ΔdblGATA1 mice (n=4) as depicted in Supplemental Figure 4, shown 
is mean ± SD. Ccl11 expression in sorted cells and whole heart homogenates was analyzed by qPCR and 
normalized to Gapdh and naïve heart homogenates. Groups were compared by one-way ANOVA followed 
by Dunnett’s multiple comparison comparing all subsets to naïve heart. ***p < 0.001. 
 
Primary cardiac fibroblasts produce eotaxins in vitro in response to IL-4 and IL-13 
We isolated primary fibroblasts from the hearts of naïve adult WT mice to determine if cardiac fibroblasts 
could produce CCL11 in response to Th2 cytokines. In vitro culture of fibroblasts with the Th2 cytokines IL-
4 and IL-13, but not IL-5, induced Ccl11 mRNA expression (Figure 15A) and secretion into the cell culture 
medium (Figure 15B). At 100 ng/ml, IL-13 was more potent than IL-4 in inducing CCL11 at the late time 
points (Figure 15A, B). The Th1 and Th17 cytokines IFNγ and IL-17A did not induce CCL11 (data not shown). 
This confirms that cardiac fibroblasts produce CCL11 and do so in response to key Th2 cytokines IL-4 and IL-
13. 
Surprisingly, IL-4 and IL-13 also induced CCL24 expression in cardiac fibroblasts (Figure 15C, D) although at 
a much lower magnitude than CCL11. This is consistent with the observation that higher expression of CCL24 
was detected in CD140a+ fibroblasts of IFNγ-/-IL-17A-/-ΔdblGATA1 mice compared to ΔdblGATA1 mice 
(Figure 12B).  
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IL-4 and IL-13 induce CCL24 in macrophages 
To determine if Th2 cytokines could also induce eotaxins in macrophages, we cultured bone marrow-
derived macrophages with different cytokines. As expected, IFNγ and IL-17A did not induce eotaxins in 
macrophages (data not shown). CCL11 was not induced in Macrophages in response to Th2 cytokines 
(Figure 15E, F). However, they secreted large amounts of CCL24 after stimulation with IL-4 and IL-13 (Figure 
15G, H). These data support macrophages as potent producers of CCL24. The increased expression of IL-4 
and IL-13 from T cells in IFNγ-/-IL-17A-/- compared to WT mice189 may explain the increased eotaxin 
expression in these mice.  
 
Figure 15: IL-4 and IL-13 induce CCL11 in cardiac fibroblasts and CCL24 in macrophages  
Adult mouse cardiac fibroblasts (A-D) and bone marrow-derived macrophages (E-H) from naïve WT mice 
were cultured in the presence of indicated cytokines at 100 ng/ml or without cytokines (control). (A, C, E, 
G) Ccl11 and Ccl24 mRNA expression was measured by qPCR and normalized to Gapdh and untreated 
controls. (B, D, F, H) Eotaxin concentrations in cell culture supernatants were measured by ELISA at 
indicated time points. Groups were compared by one-way ANOVA followed by Dunnett’s multiple 
comparison. All groups were compared to untreated controls at day 1. Shown is mean ± SD. Data are 




Cardiac eotaxin expression is increased in patients with eosinophilic myocarditis 
To test whether eotaxins are also important for eosinophil trafficking in patients with eosinophilic 
myocarditis, we analyzed endomyocardial biopsy samples. Patients with eosinophilic myocarditis had 
increased numbers of heart-infiltrating eosinophils compared to patients with chronic lymphocytic 
myocarditis (Figure 16A, B). Expression of CCL11 and CCL26 (an eotaxin specific to humans and a 
pseudogene in mice) was increased in eosinophilic myocarditis patients compared to chronic lymphocytic 
myocarditis patients (Figure 16C). CCL11 was detected in all samples regardless of diagnosis. In contrast, 
CCL26 was detected in 75% of eosinophilic myocarditis patients but only in 50% of chronic lymphocytic 
myocarditis patients (Figure 16C). CCL24 was detected in some of the eosinophilic myocarditis biopsies but 
in none of the chronic lymphocytic myocarditis samples (Figure 16C). It is possible that CCL24 is expressed 
in the heart only in the context of eosinophilic myocarditis. Expression of CCL11 and CCL26 correlated 
positively with the number of infiltrating eosinophils in the biopsies (Figure 16D). The significant increase 
in eotaxin expression in the hearts of patients with eosinophilic myocarditis and the correlation of eotaxin 
expression with eosinophil infiltration suggest that eotaxins are important for eosinophil trafficking to the 




Figure 16: Eotaxins are increased in the hearts of patients with eosinophilic myocarditis  
A) Eosinophil infiltration was quantified on H&E-stained biopsy sections. B) Representative images of (A). 
C) Eotaxin mRNA expression in endomyocardial biopsy samples is shown as fold expression relative to HPRT 
(2-ΔCt). A, C) Groups were compared by Mann-Whitney U-test. D) Linear regression of eotaxin mRNA 
expression on the number of infiltrating eosinophils. Dashed lines indicate 95% confidence intervals. CLM, 






Eosinophils can infiltrate many different organs in response to multiple local stimuli, such as chemokines 
and lipid mediators190. In this study, we present evidence that eosinophil trafficking to the heart in 
eosinophilic myocarditis depends on the chemokine receptor CCR3 and expression of its ligands CCL11, 
CCL24, and CCL26 in the heart in a mouse model and in patients with eosinophilic myocarditis. This is the 
first description of a precise pathway that recruits eosinophils to the heart. We identified the cell types 
producing eotaxins in the heart and showed that their expression in cardiac fibroblasts and macrophages is 
controlled by two cytokines, IL-4 and IL-13 (Figure 17). These findings enhance our understanding of how 
eosinophils contribute to cardiac pathology and provide insights into the regulation of eosinophilic heart 
disease and eosinophilic autoimmune diseases in general. Moreover, it opens new therapeutic avenues to 
prevent eosinophil-mediated heart damage.  
 
Figure 17: Model of eosinophil trafficking to the heart during eosinophilic myocarditis 
 
We demonstrated that CCR3 is required for eosinophil trafficking to the heart using adoptive transfer and 
genetic methods. IFNγ-/-IL-17A-/-CCR3-/- mice showed a dramatic reduction of eosinophils in the heart 
compared to IFNγ-/-IL-17A-/- mice. In addition, only CCR3+/+, but not CCR3-/-, adoptively transferred 
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eosinophils were recovered from the heart of eosinophil-deficient recipients with myocarditis. Using an 
adoptive transfer system permitted us to exclude effects of local eosinophil proliferation and positive 
feedback loops, such as eosinophil-derived IL-4 and IL-13 increasing local eotaxin production by other cell 
types. Additionally, this approach allowed us to distinguish between consequences of CCR3 expression in 
eosinophils versus other cell types, which is still a controversial issue in the mouse200, 201. 
While CCR3 in humans can bind ligands other than eotaxins, mouse CCR3 is only known to bind the mouse 
chemokines CCL11 and CCL24190, 191. Together with the results from our adoptive transfer experiments, this 
implies that the high eotaxin expression in IFNγ-/-IL-17A-/-ΔdblGATA1 mice is responsible for eosinophil 
accumulation in the heart. This is consistent with our previous findings that NK cell depletion results in 
increased eotaxin expression and eosinophil infiltration in the heart187. We only observed these differences 
between ΔdblGATA1 and IFNγ-/-IL-17A-/-ΔdblGATA1 mice in the heart. The intestine showed efficient 
CCR3+/+ eosinophil trafficking in both recipients. This suggests that the severe, Th2-driven EAM developing 
in the absence of IFNγ and IL-17A is necessary for high cardiac eotaxin expression and eosinophilic 
myocarditis. 
We identified the cellular sources of eotaxins in the heart. CCL11 was produced by interstitial CD140a+ 
cardiac fibroblasts and was detectable in ΔdblGATA1 and IFNγ-/-IL-17A-/-ΔdblGATA1 mice. While not studied 
in the heart, CCL11 expression in experimental asthma was found in the peribronchial and perivascular 
regions, perhaps consistent with expression by fibroblasts, and in areas of severe inflammation72. In DSS-
induced colitis, intestinal macrophages expressed CCL1173. Using immunohistochemistry, we detected 
CCL24+ cells only in the hearts of immunized IFNγ-/-IL-17A-/-ΔdblGATA1 mice where they localized to 
inflammatory foci. We identified these cells as F4/80+ macrophages. A previous study noticed Ccl24 
expression by microarray in CX3CR1+ cardiac macrophages, although other cell types were not analyzed202. 
In experimental asthma, CCL24 was expressed in the same areas as CCL11 and in bronchoalveolar lavage 
fluid72. Thus, multiple cell types are capable of CCL11 and/or CCL24 expression and differ between organs. 
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Our in vitro experiments showed that cardiac fibroblasts expressed CCL11 and, to a much lesser extent, 
CCL24 in response to IL-4 or IL-13 stimulation. Macrophages responded to IL-4 and IL-13 stimulation with 
CCL24 expression; CCL11 was not induced. The ability of IL-4 and IL-13 to elicit eotaxins is known203-205, but 
has not been tested in cardiac fibroblasts. We speculate that T cells and type 2 innate lymphoid cells are 
major producers of IL-4 and IL-13, respectively and control eotaxin production in the heart.  
Ccl24 is upregulated over 100-fold while Ccl11 is upregulated 20-fold in EAM, suggesting that CCL24 may 
be more important for eosinophil trafficking to the heart. This would be similar to allergic lung 
inflammation, in which eosinophil trafficking is controlled by CCL2472 but different from the intestine and 
thymus, in which eosinophil trafficking is regulated by CCL1169. The relative importance of CCL11 versus 
CCL24 in the heart remains to be determined. 
Analyzing endomyocardial biopsies, we found that CCL11 and CCL26 expression was increased in patients 
with eosinophilic myocarditis compared to chronic lymphocytic myocarditis (17-fold and 47-fold, 
respectively) and was positively correlated with the number of infiltrating eosinophils. We conclude that 
eosinophil trafficking to the heart in myocarditis patients likely occurs in response to eotaxin signaling. We 
speculate that CCL11 and CCL26 may both recruit eosinophils to the heart. An upregulation of CCL11 and 
CCL26 is also observed in patients with atopic dermatitis206-208, while only CCL26 is upregulated in 
eosinophilic esophagitis and asthma209, 210.  
Eotaxin expression in the heart has not been studied in the context of disease. In healthy human heart 
tissue CCL11 and CCL26, but not CCL24, were detected by northern blot 75-77. CCL24 mRNA was detectable 
in 2/11 eosinophilic myocarditis biopsies but none of the chronic lymphocytic myocarditis biopsies. 
However, the mRNA expression level of CCL24 was much lower than that of CCL11 and CCL26 and, thus, 
may not be important. In this aspect, the mouse model of myocarditis, where CCL11 and CCL24 are highly 
upregulated, differs from the patient samples. We did not determine eotaxin protein levels in the 
endomyocardial biopsies. Follow-up studies should measure eotaxin in the heart and serum. 
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The cellular source and regulation of eotaxins has not been studied in the human heart. In ulcerative colitis, 
CCL26 was expressed in intestinal nerve ganglia211 and CCL11 in intestinal macrophages and epithelial 
cells73. In EGPA, CCL26 was detected in endothelial cells, nasal epithelium, and other cells212. In asthmatics, 
CCL26 is expressed in bronchial epithelial cells209. Similar to our observations in the mouse, eotaxin-
production in various human cell types is induced by IL-4 and/or IL-13203-205, 207, 209, 213, 214. Depending on the 
cell type, this stimulation results in CCL11, CC24, or CCL26 production. This pathway likely also regulates 
eotaxin production in the human heart during myocarditis. 
In this study, we demonstrate the importance of eotaxins and CCR3 for eosinophil localization to the heart. 
Several therapeutics blocking this pathway are being evaluated in allergic diseases215-217, where they 
decrease tissue eosinophilia. Ongoing trials are assessing CCL11 blockade in the eosinophilic autoimmune 
diseases ulcerative colitis and bullous pemphigoid (ClinicalTrials.gov identifiers: NCT01671956, 
NCT02226146). However, none of the treatments have been studied in eosinophilic myocarditis, HES or 
EGPA. The potential of targeting eotaxins or CCR3 to prevent eosinophil-mediated heart damage remains 





Chapter 4: Eosinophil-derived IL-4 drives heart failure 
This chapter was published in the Journal of Experimental Medicine: 
Diny NL, Baldeviano GC, Talor MV, Barin JG, Ong S, Bedja D, Hays AG, Gilotra NA, Coppens I, Rose NR, 
Čiháková D. Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated 
cardiomyopathy. J Exp Med. 2017 Mar 16. [Epub ahead of print]. (Copyright: the authors.) 
Summary 
Inflammatory dilated cardiomyopathy (DCMi) is a major cause of heart failure in children and young adults. 
DCMi develops in up to 30% of myocarditis patients, but the mechanisms involved in disease progression 
are poorly understood. Patients with eosinophilia frequently develop cardiomyopathy. We used the 
experimental autoimmune myocarditis (EAM) model to determine the role of eosinophils in myocarditis 
and DCMi. Eosinophils were dispensable for myocarditis induction but required for progression to DCMi. 
Eosinophil-deficient ΔdblGATA1 mice, in contrast to WT mice, showed no signs of heart failure by 
echocardiography. Induction of EAM in hypereosinophilic IL-5Tg mice resulted in eosinophilic myocarditis 
with severe atrial inflammation, which progressed to severe DCMi. This was not a direct effect of IL-5 as IL-
5TgΔdblGATA1 mice were protected from DCMi while IL-5-/- mice exhibited DCMi comparable to WT mice. 
Eosinophils drove progression to DCMi through their production of IL-4. Our experiments showed 
eosinophils were the major IL-4 expressing cell type in the heart during EAM, IL-4-/- mice were protected 
from DCMi like ΔdblGATA1 mice, and eosinophil-specific IL-4 deletion resulted in improved heart function. 
In conclusion, eosinophils drive progression of myocarditis to DCMi, cause severe DCMi when present in 




Myocarditis, the inflammation of the heart muscle in the absence of an ischemic event, can cause sudden 
cardiac death and heart failure 5, 12. While most myocarditis patients recover from the acute illness, a major 
burden lies in the sequela inflammatory dilated cardiomyopathy (DCMi). About 9-16% of patients with new 
onset DCMi have evidence of prior myocarditis 48, 49, 218, yet the mechanisms involved in disease progression 
are poorly understood 219. DCMi is the major cause of heart failure in patients under 40 years of age. The 5-
year survival rate is less than 50% 138, 173. Currently, the only option for patients with end-stage DCMi is 
heart transplantation. Even if a transplant is available, patients with a history of myocarditis have a 
particularly poor survival rate 174. No drugs are available to arrest or delay development of DCMi or to 
improve long-term survival. Thus, there is an urgent need to better understand the progression of 
myocarditis to DCMi and to develop new therapeutic approaches to prevent it.  
Eosinophils play an important role in heart disease. Cardiac complications occur in about 20-50% of patients 
with prolonged elevation of eosinophil numbers, such as hypereosinophilic syndrome (HES) and 
eosinophilic granulomatosis with polyangiitis, and are a major cause of mortality 32-35, 182. Predominant 
infiltration of the heart with eosinophils characterizes the clinically-recognized subtype eosinophilic 
myocarditis. In addition to HES and eosinophilic granulomatosis with polyangiitis patients, eosinophilic 
myocarditis can develop in patients with parasitic infections, in response to toxins or drugs, or by unknown 
etiology 14, 24. Eosinophilic myocarditis is rarely diagnosed clinically but is found in up to 0.5% of patients in 
a hospital autopsy series 153 and about 7% of explanted hearts from transplant patients 152-154. It is not known 
at what rate eosinophilic myocarditis patients progress to DCMi or how this rate compares against other 
myocarditis subtypes. 
Eosinophils infiltrate the site of inflammation and release preformed toxic granule proteins, cytokines, and 
growth factors, thereby contributing to tissue injury and remodeling67. Eosinophils have been thought to 
activate other cardiac cell types, to be directly cytotoxic to the endocardium or cardiomyocytes, or to 
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release granule proteins or pro-thrombotic factors 39, 43-46, 186. However, many of these studies are purely 
observational and the proposed pathogenic mechanisms have not been thoroughly tested. Others have 
demonstrated eosinophilic myocarditis developing after infection with various parasites 220-225 or 
spontaneously in DBA/2 mice 226-228, Socs1-deficient mice229, and Bcl6-deficient mice 230. However, none of 
these studies have examined the importance of eosinophils for myocarditis severity, their role in 
progression to DCMi, or how eosinophils damage the heart. The NIH workshop report on the Research 
Needs of Eosinophil-Associated Diseases points out an urgent need for preclinical models and mechanistic 
understanding of eosinophil-mediated cardiac damage 184.  
To study myocarditis and DCMi, our laboratory has developed an animal model of experimental 
autoimmune myocarditis (EAM) 58, 60. Mice lacking both the key T helper 1 (Th1) and Th17 cytokines IFNγ 
and IL-17A developed a rapidly fatal eosinophilic myocarditis after induction of EAM. Ablation of eosinophils 
in these mice improved survival 189. In another model, natural killer cell depletion resulted in increased 
eosinophil infiltration in the heart, aggravating myocarditis 187. These results suggest that eosinophils are 
highly pathogenic in myocarditis and DCMi. In this study, we used eosinophil-deficient and 
hypereosinophilic mouse models to examine the impact of eosinophils in myocarditis and its sequela DCMi. 
Moreover, we identified the mechanisms by which eosinophils contribute to pathology. 
Materials and Methods 
Patients 
Patients with endomyocardial biopsy (EMB)-confirmed eosinophilic myocarditis for whom cardiac magnetic 
resonance imaging was also available from 2000-2014 were retrospectively identified at the Johns Hopkins 
Hospital, Department of Cardiology. EMB of the right ventricular septum was performed using the Argon 
Jawz Endomyocardial Bioptome. A cardiac pathologist examined all specimens at a minimum of four section 
levels with typical stains 105. Diagnosis of eosinophilic myocarditis was established using the Dallas Criteria 
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for myocarditis and presence of eosinophilic infiltrate as detected on H&E-stained sections1. Patients 
underwent clinically indicated cardiac magnetic resonance with a 1.5-T scanner (Siemens Healthcare, 
Avanto, Erlangen, Germany) including standard cine and late gadolinium enhancement studies covering the 
whole heart. Analysis was performed on a dedicated workstation by an experienced observer. The study 
was approved by the Johns Hopkins Institutional Review Board. 
Mice 
IL-5Tg (founder line NJ.1638) 195 and EoCre mice 231 were kindly provided on the BALB/c background by Drs. 
James and Nancy Lee, Mayo Clinic, Scottsdale. IL-5-/- mice 232 were kindly provided by Dr. Marc Rothenberg. 
BALB/cJ wildtype (WT, Jackson Laboratories Stock #651), ΔdblGATA1 (194, #5653), IL-4-/- (233, #2496), 4get 
(234, #4190), IL-4/13flox/flox (235, #15859), and ROSA-DTA (236, #9670) mice were purchased from Jackson 
Laboratories. All mice were on the BALB/c background. Mice were housed in specific pathogen-free animal 
facilities at the Johns Hopkins University. Experiments were conducted on 6–10-weeks-old age-matched 
male mice in compliance with the Animal Welfare Act and the principles set forth in the Guide for the Care 
and Use of Laboratory Animals. All methods and protocols were approved by the Animal Care and Use 
Committee of Johns Hopkins University. 
Induction of EAM  
To induce EAM, mice received subcutaneous immunizations on days 0 and 7 of 100 µg myosin heavy chain-
α (MyHC)614-629 peptide (Ac-SLKLMATLFSTYASAD, Genscript) 237emulsified in CFA (Sigma-Aldrich) 
supplemented to 5 mg/ml heat-killed Mycobacterium tuberculosis strain H37Ra (Difco). On day 0, mice also 
received 500 ng pertussis toxin intraperitoneally (List Biologicals) 60. 
Assessment of EAM severity and fibrosis 
Heart tissue was fixed in SafeFix solution (Thermo Fisher Scientific), embedded, and cut into 5-µm serial 
sections. Ventricular inflammation was scored by microscopic assessment of the area of infiltration with 
hematopoietic cells on H&E stained sections according to the following scale: grade 0, no inflammation; 
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grade 1, <10% of the heart section is infiltrated; grade 2, 10-30%; grade 3, 30-50%; grade 4, 50-90%; grade 
5, >90%. Ventricular fibrosis was scored on Masson’s trichrome-stained sections according to the same 
scale. Atrial inflammation and fibrosis was scored on the following scale: none (0), mild (1), moderate (2), 
severe (3). Grading was performed by two independent, blinded investigators and averaged 60.  
Light microscopy 
Images were acquired on a Olympus BX43 microscope with a Olympus DP72 camera using cellSens Standard 
version 1.4.1 (Olympus). 
Electron microscopy 
Mice were anesthetized, the heart was removed, and the left ventricle was cut into 2-3mm3 pieces and 
immediately fixed in 2.5% glutaraldehyde (EM grade, Electron Microscopy Sciences, Hatfield, PA) dissolved 
in 0.1M Na cacodylate (pH7.4) for 2h at room temperature. Samples were processed as described 238 before 
examination with a Philips CM120 Electron Microscope (Eindhoven, the Netherlands) under 80 kV. Images 
were acquired with AMT Image Capture Engine V602 (Advanced Microscopy Techniques). 
Echocardiography 
Transthoracic echocardiography was performed using the Acuson Sequoia C256 ultrasonic imaging system 
(Siemens) with a 13 MHz transducer. Conscious, depilated mice were held in a supine position. The heart 
was imaged in the two-dimensional mode in the parasternal short axis view. An M-mode cursor was 
positioned perpendicular to the interventricular septum and the left ventricular posterior wall at the level 
of the papillary muscles. The LVEDD, LVESD, interventricular septal wall thickness at end-diastole, and LV 
posterior wall thickness at end-diastole were measured three times for each mouse from a frozen M-mode 





For flow cytometry analysis, single cell suspensions were made from mouse spleen by mechanical 
dissociation followed by red blood cell lysis with ACK lysis buffer (Quality Biologicals). Heart-infiltrating 
leukocytes were isolated by perfusing mouse hearts for 3 min with PBS 0.5% FBS, and digested for 30 min 
at 37°C in gentleMACS C Tubes (Miltenyi Biotec) with 3000 U/ml Collagenase II and 90 U/ml DNase I 
(Worthington). For intracellular cytokine staining, cells were stimulated in vitro for 5h with 50 ng/ml phorbol 
12-myristate 13-acetate, 750 ng/ml ionomycin (Sigma), GolgiStop, and GolgiPlug (BD Biosciences) prior to 
staining. Viability was determined by LIVE/DEAD staining according to manufacturer’s instructions (Life 
Technologies). For intracellular cytokine staining, cells were resuspended in Cytofix/Cytoperm (BD 
Biosciences). Cells were blocked with anti­CD16/CD32 (eBioscience), and were stained with 
fluorochrome-conjugated monoclonal antibodies (eBioscience, BD Biosciences, BioLegend). For absolute 
quantification, viable cells were counted with Trypan blue or using CountBright beads (Thermo Fisher 
Scientific). Samples were acquired on an LSR II cytometer running FACSDiva 6 (BD Biosciences). Data were 
analyzed with FlowJo 10 (TreeStar). 
Isolation of primary adult mouse cardiomyocytes 
To isolate cardiomyocytes and cardiac fibroblasts, the heart was dissected from 6–8-wk-old male mice 
pretreated with heparin as previously described197. The aorta was cannulated, and the heart was perfused 
with calcium-free perfusion buffer, and digested with 3000 U/ml collagenase II (Worthington) and 0.05 
mg/ml Protease XIV (Sigma-Aldrich) for 15 min at 30°C followed by mechanical dissociation. 
Cardiomyocytes were separated from resulting suspensions by their rapid spontaneous precipitation. 
Isolated CMs were cultured in mouse laminin-coated plates. Non-adherent cells were washed off after 1h. 
Hydroxyproline assay 
Heart samples were weighed, homogenized in de-ionized water, and hydrolyzed overnight in 6N HCl at 
120°C. Lysates were transferred to and desiccated in 96-well plates, and reconstituted in de-ionized water. 
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After incubation with 50 mM Chloramine T (Sigma-Aldrich) followed by 1 M dimethylaminobenzaldehyde 
(Sigma-Aldrich), the OD values were read at 570 nm. The concentration of hydroxyproline was determined 
by a 1–100 µg/ml standard curve of hydroxyproline (Sigma-Aldrich) and normalized to starting heart tissue 
mass. 
ELISA  
Sera were stored at -80˚C prior to analysis. IL-5 was determined by quantitative sandwich ELISA according 
to manufacturers’ recommended protocols (R&D Systems). For anti-myosin IgG ELISA, plates were coated 
with 0.5 µg/ml MyHC614-629 peptide (Ac-SLKLMATLFSTYASAD, Genscript) overnight at 4°C, washed with 1X 
PBS 2% FBS, and incubated with sera for 2h at room temperature. Plates were washed and incubated with 
secondary anti-mouse IgG antibody (Abcam) diluted 1:1000 in 1XPBS for 2h at room temperature. Plates 
were washed and developed with Alkaline Phosphatase (Biorad) and OD was read at 405 nm. 
Quantitative PCR 
Tissue RNA was extracted in TRIzol (Invitrogen) and quantitated. cDNA was synthesized with the High 
Capacity cDNA Reverse Transcription kit (Life Technologies), amplified with iQ SYBR Green Mastermix (Bio-
Rad), and acquired on the MyiQ2 thermocycler (Bio-Rad) running iQ5 software (Bio-Rad). Data were 
analyzed by the 2–ΔΔCt method198, normalizing threshold cycles first to Gapdh or Hprt expression, and then 
to controls. Primer sequences are listed in Table 7. 
Statistics 
Two groups with normally distributed data were analyzed using student’s t-test. Mann-Whitney test was 
used for nonparametric data. Multiple group analysis was performed by one-way ANOVA followed by 
Tukey’s multiple comparisons test for continuous variables or by Kruskal-Wallis test followed by Dunn’s 
multiple comparisons test for nonparametric data. Calculations were performed in Prism 6 (GraphPad 
Software Inc.). P values <0.05 were considered statistically significant and are denoted by asterisk: *p<0.05, 
**p<0.01, ***p<0.001.  
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Table 7: Primer sequences 
Gene Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) 
Ccl11 gaatcaccaacaacagatgcac tcctggacccacttcttctt 
Ccl24 tcttagggcccttcttggtg aattccagaaaaccgagtgg 
Col1a2 agcaggtccttggaaacctt aaggagtttcatctggccct 
Col3a1 gtgaacggggcgaagctggtt gcggctcctggaagcccatttg 
Gapdh tcctcctcagaccgctttt tctgctggagtccccttg 
Gata3 ctcgggcattcgtacatggaa ggatacctctgcaccgtagc 
Hprt tcagtcaacgggggacataaa ggggctgtactgcttaaccag 
Mmp2 tttgctcgggccttaaaagtat ccatcaaacgggtatccatctc 
Mmp9 tgcccatttcgacgacgac gtgcaggccgaataggagc 
Rorc atcctgtaatggcttgtggg tcaaccagcaccagacagag 
Tbx21 atcctgtaatggcttgtggg tcaaccagcaccagacagag 
Timp1 gcaactcggacctggtcataa cggcccgtgatgagaaact 
Timp2 cttctgcaactccgacatcgt ggggcatcttactgaagcctc 
Results 
Eosinophil-deficient mice develop myocarditis but are protected from dilated cardiomyopathy 
To study the mechanism of eosinophil-mediated damage in myocarditis and its sequela DCMi, we used 
eosinophil-deficient ΔdblGATA1 mice. In these mice, a deletion in the promoter of Gata1 blocks eosinophil 
development in the bone marrow 194. Myocarditis was induced in wildtype (WT) and ΔdblGATA1 mice and 
the degree of inflammation was compared on day 21 of EAM. ΔdblGATA1 mice developed myocarditis with 
similar severity as WT mice (Figure 18A, B). Moreover, no differences were observed in the number of heart-
infiltrating CD45+ cells by flow cytometry at day 21 of EAM (Figure 18C).  
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In WT mice, EAM progresses to DCMi 12. Surprisingly, typical signs of ventricular dilation were present in 
WT, but not ΔdblGATA1 mice examined by echocardiography (Figure 18D). ΔdblGATA1 mice had preserved 
left ventricular (LV) end-diastolic (LVEDD) and end-systolic (LVESD) diameters and preserved ejection 
fraction (EF) at day 42 of EAM (Figure 18E-G). ΔdblGATA1 mice were also protected from the increase in LV 
mass and thinning of the LV wall (relative wall thickness, RWT) seen in WT mice (Figure 18H-I). These results 
indicate that eosinophils are not required for EAM development, but are necessary for progression of 
myocarditis to DCMi. 
ΔdblGATA1 mice develop fibrosis but show altered tissue remodeling  
Progression to DCMi is associated with changes in the connective tissue in the heart, namely fibrosis and 
tissue remodeling. We previously reported on EAM in IL-17A-/- and IL-17RA-/- mice, in which protection from 
DCMi is associated with reduced fibrosis 197, 240. ΔdblGATA1 mice, however, developed fibrosis to a similar 
degree as WT mice. Fibrosis was assessed by scoring of Masson’s trichrome stained heart sections (Figure 
19A) and quantitation of total cardiac hydroxyproline, a collagen-specific amino acid (Figure 19B). These 
results demonstrate that heart function can be preserved despite development of cardiac fibrosis. 
Protection of IL-17A-/- mice from DCMi is associated with differential expression of Col1a2, Col3, Timp1, and 
Mmp9 240. Expression of these genes was not changed in ΔdblGATA1 mice (Figure 19C). However, other 
tissue remodeling-associated genes, Mmp2 and its regulator Timp2, were decreased in ΔdblGATA1 mice 
(Figure 19D). This indicates that eosinophils promote DCMi through pathways that are identifiably distinct 
from those driven by IL-17 signaling. High serum MMP2 levels are associated with a poor prognosis in acute 





Figure 18: Eosinophil-deficient mice develop EAM, but are protected from DCMi  
A) Representative images of H&E stained heart sections from day 21 of EAM. B) The area of infiltration on 
H&E stained heart sections was scored on day 21 of EAM (C) Total heart-infiltrating CD45+ cells at day 21 
of EAM were determined by flow cytometry (D-I) Echocardiography in WT and ΔdblGATA1 mice on day 45 
of EAM D) Representative M-mode pictures. E-I) Grey bands indicate 95% confidence interval for naïve WT 
mice. B, C, E-I) Groups were compared using t-test. Data are representative of 3-5 independent experiments 






















Figure 19: Protection of ΔdblGATA1 mice from DCMi is accompanied by changes in tissue remodeling-
associated genes not changes in heart-infiltrating cell populations 
A-D) Mice were analyzed at day 45 of EAM. A, B) The extent of fibrosis was determined by scoring fibrotic 
areas on histological sections from 5 experiments (A) and by quantifying the amino acid hydroxyproline in 
heart samples from 2 experiments (B). C, D) Gene expression in heart homogenates was analyzed by qPCR. 
Data are representative of 2-3 independent experiments with 5-8 mice/group. E) Frequency of heart 
infiltrating cells was determined by flow cytometry on day 21 of EAM. Data are combined from different 
experiments. Cell types were gated as follows: neutrophils: CD11b+Ly6G+, T cells: CD11b-CD3+CD4+ or CD8+, 
B cells: CD11b-B220+, NK cells: CD11b-CD3-NKp46+, monocytes / macrophages: CD11b+Ly6G-Ly6C+, 
basophils: CD11b+Ly6G-Ly6C-FcεRIα+DX5+, mast cells: CD11b+Ly6G-Ly6C-FcεRIα+ CD117+. F) Expression of 
transcription factors was determined by quantitative PCR from heart homogenates from day 21 of EAM and 
normalized to expression of CD3 and WT controls. Data are representative of 2 independent experiments 
with 4-8 mice/group. Groups were compared by Mann-Whitney test (A) or t-test (B-F). Asterisk indicate 










Lack of eosinophils does not alter cardiac inflammatory infiltrate in EAM 
In WT mice, eosinophils accounted for 1-3% of heart-infiltrating cells at day 21, the peak of EAM (Figure 
20A, B). As expected, eosinophils were not detected in ΔdblGATA1 mice (Figure 20A, B). We first 
hypothesized that eosinophils may affect the makeup of the cellular infiltrate in myocarditis. However, the 
lack of eosinophils in ΔdblGATA1 mice did not affect the composition of heart-infiltrating cell populations 
(Figure 20B, Figure 19E). We did not observe any differences in the percentage of heart-infiltrating 
neutrophils, T cells, B cells, NK cells, monocytes / macrophages, basophils, or mast cells. Production of IL-
17A, IFNγ, IL-4, and IL-13 by heart-infiltrating T helper cells was comparable between WT and ΔdblGATA1 
mice (Figure 20C, Figure 19F), indicating that the lack of eosinophils did not affect T cell polarization. These 





Figure 20: Lack of eosinophils does not alter inflammatory infiltrate in EAM 
A-C) Frequency of heart-infiltrating cells was determined by flow cytometry on day 21 of EAM. A) Flow plots 
show viable CD45+ cells. C) Cytokine production by heart-infiltrating CD4+ T cells. Data are representative 




IL-5Tg mice develop eosinophilic myocarditis 
To address whether increased levels of eosinophils would aggravate myocarditis and DCMi, we used 
transgenic mice expressing IL-5 under the CD3 promoter (IL-5Tg). These mice express high serum levels of 
IL-5, a key cytokine for eosinophilopoiesis and eosinophil survival, and develop extensive peripheral 
eosinophilia195. Following immunization, IL-5Tg mice developed severe eosinophilic myocarditis (Figure 
21A). Scoring of the degree of inflammation revealed a trend towards more severe inflammation in the 
ventricles (Figure 21A, B) and significantly more severe inflammation in the atria of IL-5Tg mice (Figure 21A, 
C). This resulted in an increased number of heart-infiltrating CD45+ cells in IL-5Tg compared to WT mice 
(Figure 21D). As evident from the histology, eosinophils comprised a large proportion of heart-infiltrating 
cells (Figure 21A, high magnification inserts). We quantified heart-infiltrating cell types using flow 
cytometry. Eosinophils accounted for over 60% of CD45+ cells in the hearts of IL-5Tg mice compared to only 
3% in WT mice (Figure 21D). This corresponded to a dramatic difference in absolute eosinophil numbers in 
both atria and ventricles (Figure 22A). Due to this tremendous increase in heart-infiltrating eosinophils and 
overall increase of CD45+ cells, the absolute numbers of other cell populations were either not different or 
higher in IL-5Tg mice (Figure 22B). A possible explanation for the severe eosinophilic atrial inflammation 
was increased expression of eotaxins in the atria of IL-5Tg mice (Figure 22C). Eotaxins are key chemokines 
for eosinophil trafficking to the heart 74. Taken together, these results show that IL-5Tg mice develop severe 





Figure 21: IL-5 transgenic mice develop severe eosinophilic myocarditis 
A) Representative images of H&E stained heart sections from day 21 of EAM. B, C) Scoring of inflammation 
in the ventricles (B) and atria (C). D, E) Total heart-infiltrating CD45+ cells (D) and heart-infiltrating cell 
populations (E) were quantified by flow cytometry. Data are representative of 2-3 independent experiments 
with 4-5 mice/group. Groups were compared using Mann-Whitney test (B, C) or t-test (D). Grey scale bars: 


























Figure 22: Atrial versus ventricular inflammation in IL-5Tg mice and an eosinophilic myocarditis patient 
A-C) Mice were analyzed at day 21 of EAM. A) Gene expression in ventricles and atria was determined by 
qPCR and normalized to Gapdh. B, C) Absolute numbers of heart-infiltrating cell types at day 21 of EAM 
were determined using flow cytometry. D, E) Eosinophilic myocarditis in a 41-year-old female patient with 
a history of hypereosinophilic syndrome. D) Cardiovascular magnetic resonance (4-Chamber view) shows 
late gadolinium enhancement (LGE) in the right (blue arrow) and left atrial free wall (yellow arrow) and 
focal subendocardial LGE of the inferolateral myocardial wall of the left ventricle (red arrow). E) H&E-
stained endomyocardial biopsy from the right ventricular septum showing eosinophilic infiltration in the 
myocardium. A, C) Groups were compared by one-way ANOVA followed by Tukey’s multiple comparison 
test. A) Data shown are from one experiment with 4 mice/group. B) For each population, WT and IL-5Tg 
were compared by t-test. Data are representative of 2 independent experiments with 5-6 mice/group. C) 
Data are representative of 2 independent experiments with 3-4 mice/group. Asterisk indicate significance: 









Eosinophilic atrial inflammation progresses to severe fibrosis 
By day 45 of EAM, IL-5Tg mice developed ventricular fibrosis similar to WT mice. The severe atrial 
inflammation in IL-5Tg mice progressed into extensive fibrosis of the atria, often with ongoing eosinophilic 
inflammation (Figure 23A, Figure 24A-D). We wondered if atrial inflammation/fibrosis was also a common 
feature of eosinophilic myocarditis in patients. We identified 3 patients with biopsy-confirmed eosinophilic 
myocarditis and cardiac magnetic resonance imaging seen at the Johns Hopkins Hospital, Department of 
Cardiology. Two of these three patients showed late gadolinium enhancement (LGE) in the atria, indicating 
fibrosis or inflammation of the atria. Patient 1 had relatively more atrial than ventricular involvement 
(Figure 22D, E). Patient 2 had predominantly left ventricular involvement with some LGE of the right 
ventricle.  There was less atrial involvement with patchy LGE located near the annulus. Other studies have 
also described atrial involvement either alone or together with ventricular inflammation in some cases of 
eosinophilic myocarditis and giant cell myocarditis 168, 243-247. This suggests that atrial inflammation and/or 
fibrosis may also be a feature in some eosinophilic myocarditis patients. 
Eosinophils drive severe DCMi 
To determine if large numbers of eosinophils could contribute to DCMi severity, we analyzed heart function 
over time in WT, hypereosinophilic IL-5Tg, and eosinophil-deficient ΔdblGATA1 mice. As expected, WT mice 
developed DCMi and ΔdblGATA1 mice showed no change in EF over time. IL-5Tg mice showed an even 
further reduction in EF compared to WT mice, developing very severe DCMi by day 45 of EAM (Figure 23B). 
IL-5Tg mice also progressed to more severe dilation of the left ventricle and increased LV mass compared 
to WT mice (Figure 23C-E). Thus, the level of eosinophilia correlated with DCMi severity, indicating that 




Figure 23: IL-5Tg but not IL-5TgΔdblGATA1 or IL-5-/- mice progress to severe DCMi 
A) Representative images of Masson’s trichrome stained heart sections from day 45 of EAM. B) Serial 
echocardiography was performed on day -1, 28, and 45 of EAM. EF for individual mice was normalized to 
EF of day -1. Mean ± SEM of combined data from two independent experiments with 5-8 mice per group is 
shown. C-I) Echocardiography was performed on day 45 of EAM in the indicated strains. A, C-I) Data are 
representative of 2 independent experiments with 5-9 mice/group. B-I) Groups were compared by one-way 
ANOVA followed by Tukey’s multiple comparisons test for all groups against each other. In B) % change in 
EF on day 45 was compared for all groups. Grey scale bars: 1mm, black scale bars: 100µm, red scale bars: 




IL-5 is dispensable for progression to DCMi 
To discriminate between the effects of IL-5 and eosinophils, we crossed IL-5Tg mice with ΔdblGATA1 mice. 
Resulting IL-5TgΔdblGATA1 mice had high serum levels of IL-5 but lacked eosinophils (Figure 24E, F). IL-
5TgΔdblGATA1 mice were completely protected from the decrease in EF and LV dilation seen in IL-5Tg mice 
(Figure 23B-E). Like ΔdblGATA1 mice, IL-5TgΔdblGATA1 mice were completely protected from DCMi. This 
demonstrates that high IL-5 levels were not directly responsible for progression to DCMi, but rather 
eosinophils were driving this process. 
We assessed IL-5-/- mice to determine if IL-5 is necessary for the development of DCMi following 
myocarditis. Myocarditis severity in IL-5-/- mice was comparable to WT mice (Figure 24G, H) and IL-5-/- mice 
developed DCMi with the same severity as WT mice, showing no difference in LVEDD, LVESD, EF, or RWT 
(Figure 23F-I). Together, these data led us to conclude that IL-5 was neither necessary for DCMi 
development, nor did it drive disease progression. In contrast, eosinophils were required for DCMi 
development and caused severe DCMi when present in large numbers. 
 
Figure 24: Eosinophils rather than IL-5 contribute to severe DCMi and atrial inflammation / fibrosis 
A-D) Mice were analyzed at day 45 of EAM. A) Heart sections were stained with Masson’s trichrome and 
are shown representatively for all indicated mouse strains. Mice from different experiments are shown. 
Grey scale bars: 1mm, black scale bars: 100µm. B-D) The extent of fibrosis was determined by scoring 
fibrotic areas on histological sections (B, D) and by quantifying the amino acid hydroxyproline in heart 
samples (C). B-D) Data are representative of 2 independent experiments with 5-9 mice/group. E) IL-5 
concentration in serum of naïve mice was determined by ELISA. F-H) Mice were analyzed at day 21 of EAM. 
F) Heart-infiltrating eosinophils were quantified by flow cytometry. G, H) Severity of inflammation was 
scored on H&E stained heart sections. G) Data are representative of 2 independent experiments with 5-6 
mice/group. H) Data are pooled from 2 independent experiments with 2-6 mice/group. Groups were 
compared by one-way ANOVA followed by Tukey’s multiple comparisons test (B-F) or by Mann Whitney 









Eosinophils do not cause DCMi through effects on dendritic cells, antibody production, or cytotoxic 
effects 
In allergic asthma, eosinophils are required for dendritic cell (DC) activation and suppress downstream Th17 
responses248. The frequency of cardiac DCs and expression of costimulatory molecules on their surface was 
not reduced in ΔdblGATA1 compared to WT mice on day 10 of EAM (Figure 25A). We did not observe 
differences in Th17 cells either (Figure 19, Figure 20). Eosinophils have also been reported to promote 
plasma cell survival in the bone marrow and IgA production in the intestine 249-251. While antibodies are 
neither required nor sufficient for induction of myocarditis in BALB/c mice, it is unclear whether they play 
a role in progression to DCMi12, 252, 253 and pathogenic autoantibodies have been demonstrated in other 
experimental models and in patients254, 255. ΔdblGATA1 and WT mice had comparable levels of cardiac 
myosin-specific IgG in serum on days 21 and 45, and of plasma cells on day 21 of EAM (Figure 25B, C). Thus, 
it is unlikely that eosinophils drive DCMi through effects on antibody production. Previously, eosinophil 
granule proteins were shown to activate mast cells45. We did not observe differences in mast cell numbers 
(Figure 19) or in serum IgE (not shown) between WT and ΔdblGATA1 mice.   
Eosinophils are thought to damage the heart by releasing cytotoxic granule proteins39, 43, 44, 186. We tested 
whether the granule protein eosinophil peroxidase, which is pathogenic in a colitis model256, was important 
for DCMi. Mice lacking functional eosinophil peroxidase (homozygous EoCretg/tg mice with recombination 
into the eosinophil peroxidase locus) were not protected from DCMi (Figure 25D, E). Using in vitro co-culture 
of primary cardiomyocytes from adult WT mice with eosinophils, we found no effect of eosinophils on the 
survival of cardiomyocytes (Figure 25F, G). Some cardiomyocyte necrosis was evident on the histological 
sections from all strains of mice during EAM. However, the extent of necrosis was not increased in strains 
with higher numbers of heart-infiltrating eosinophils (Figure 18A, Figure 21A). We conclude from these data 












Figure 25: Eosinophils do not drive DCMi through effects on dendritic cells, antibody production, cytotoxic 
effects on cardiomyocytes or eosinophil peroxidase 
A) Dendritic cell frequency and activation in the heart at day 10 of EAM was determined by flow cytometry. 
B) Myosin-specific IgG was quantified in serum on days 21 and 45 of EAM. C) Plasma cell frequency in the 
bone marrow of WT and ΔdblGATA1 mice on day 21 of EAM. D) Eosinophil frequency in the blood of WT 
and EoCretg/tg mice on day 45 of EAM was determined by flow cytometry. E) Echocardiography of WT and 
EoCretg/tg mice on day 45 of EAM. Mice homozygous for the EoCre transgene are functionally eosinophil 
peroxidase knockouts. F, G) Adult mouse cardiomyocytes (AMCM) from WT mice were cultured in vitro for 
20 h with or without eosinophils isolated from the blood of IL-5Tg mice. Dead (round, detached) and viable 
(adherent, rod-shaped) AMCM were counted under the microscope at 40X magnification. Viability is 





Eosinophils in the heart are activated 
Eosinophil activation results in upregulation of SiglecF257, a surface receptor that triggers eosinophil 
apoptosis as part of a negative feedback loop258-260. Eosinophils in the heart of WT and IL-5Tg mice showed 
increased expression of SiglecF compared to splenic eosinophils during EAM (Figure 26A). Eosinophils from 
IL-5Tg mice had higher SiglecF expression than WT mice in both spleen and heart. Cardiac eosinophils also 
expressed higher levels of CD11b (Figure 26B). This concurs with our previously reported findings that 
eosinophils in the heart of NK-cell depleted mice are activated during EAM showing increased expression 
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of SiglecF, CD11b, and an altered transcriptional profile as compared to splenic eosinophils from the same 
mice187.  
We used electron microscopy to determine the extent of eosinophil degranulation in the heart. The 
ultrastructure of tissue-infiltrating eosinophils was compared to blood eosinophils on cardiac sections from 
an IL-5Tg mouse (Figure 27). Blood eosinophils showed largely regular architecture of mature granules with 
an electron dense core surrounded by an electron-lucent matrix (Figure 26C, D). Granules in tissue 
eosinophils were also mostly intact without apparent signs of degranulation (Figure 26E, F). The number of 
granules was comparable in blood and tissue eosinophils (not shown). Only rarely did we observe granules 
with a loss of matrix or core as described for models of allergic asthma, colitis, or in vitro degranulation256, 
261, 262 (Figure 26E, H). Free extracellular granules or compound exocytosis of granules were not observed. 
We therefore conclude that eosinophils in the heart do not degranulate on a large scale during EAM. 
However, vesiculo-tubular organelles and ruffled membranes were very prominent in the cytoplasm of 
tissue-infiltrating eosinophils (Figure 26G, H), suggesting that eosinophils might be releasing specific granule 
contents through piecemeal degranulation. 
Figure 26: Heart-infiltrating eosinophils show an activated phenotype.  
A, B) Eosinophils were gated by flow cytometry as viable CD45+Ly6C-Ly6Glo/intSiglecF+ cells on day 21 of 
EAM. Histograms and mean fluorescent intensity (MFI) for SiglecF (A) and side scatter (SSC, B) are shown. 
Groups were compared by one-way ANOVA followed by Tukey’s multiple comparisons test for all groups 
against each other. Data are representative of 3 independent experiments with 4-6 mice/group. C-H) 
Electron microscopy of eosinophils from an IL-5Tg mouse at day 21 of EAM. Representative images of 
intravascular (blood) eosinophils (C-D) and tissue-infiltrating eosinophils (E-H) are depicted. Small inserts 
show high magnification of individual granules (C-F) or cytoplasmic vesiculo-tubular structures (G-H). Black 







Figure 27: Electron microscopy of heart-infiltrating and blood eosinophils 
Pseudocoloring: cardiomyocytes (blue), endothelial cells (green), red blood cells (red), eosinophils (pink), 
collagen fibers (yellow). 
 
Eosinophils account for the majority of IL-4 expressing cells in EAM 
Eosinophil granules harbor numerous cytokines in addition to granule proteins and can selectively release 
them upon stimulation99, 263. Of these, eosinophil-derived IL-4 has been shown to affect several 
physiological processes264-267. To assess IL-4 production by eosinophils in myocarditis, we employed the IL-
4 reporter mouse 4get, in which IL-4-expressing cells are GFP+. Eosinophils accounted for the majority (over 
60%) of IL-4-expressing cells in myocarditis in 4get mice (Figure 28A, B). Over 80% of eosinophils were GFP+ 
indicating that the vast majority of eosinophils expressed IL-4 (Figure 28C, D). Hence, eosinophils are the 
major IL-4-producing cells in myocarditis. 
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IL-4-/- mice are protected from DCMi 
Next, we determined the role of IL-4 in myocarditis and DCMi. We previously published that IL-4-/- mice 
develop myocarditis with the same severity as WT mice239. When we analyzed heart function in IL-4-/- mice 
by echocardiography, we found that they were completely protected from DCMi. Like ΔdblGATA1 mice, IL-
4-/- mice had reduced LVESD and LVEDD and preserved EF (Figure 29A). Taken together with the data 
showing that eosinophils comprise the majority of IL-4-expressing cells, these results strongly suggested 
that eosinophils drive progression of myocarditis to DCMi through their production of IL-4.  
Eosinophil-specific deletion of IL-4 ameliorates DCMi 
To assess whether IL-4 derived from eosinophils is necessary for DCMi development, we generated mice 
with eosinophil-specific IL-4 and IL-13 deletion. We crossed mice with eosinophil-specific Cre recombinase 
expression (EoCre) with IL-4/13fl/fl mice. Resulting EoCrewt/tgIL-4/13fl/fl mice developed myocarditis similar 
to WT mice. Absolute numbers and composition of infiltrating CD45+ cells were comparable (Figure 29B, C). 
However, at day 45 of EAM, EoCrewt/tgIL-4/13fl/fl mice showed decreased LVESD, increased EF and decreased 
LV mass compared to WT controls (Figure 29B). Ventricular and atrial fibrosis was similar in WT, IL-4-/-, and 
EoCrewt/tgIL-4/13fl/fl mice (Figure 30A-C).These results show that eosinophils drive dilated cardiomyopathy 
through the production of IL-4. Eosinophil-specific IL-4 deletion resulted in a milder phenotype compared 
to IL-4-/- mice (Figure 29). This is likely a result of incomplete Cre-mediated recombination of the IL-4/13 
locus; crossing EoCre mice to the deleter strain ROSA-DTA resulted in a reduction, but not complete 
ablation, of eosinophils during EAM (Figure 30D). We can not exclude effects from residual IL-4 production 
by other cell types or other eosinophil-derived mediators. Expression of tissue remodling-associated genes 
Mmp2 and Timp2, which was reduced in ΔdblGATA1 mice, was also diminished in EoCrewt/tgIL-4/13fl/fl mice 
(Figure 30E), suggesting that these changes in gene expression are mediated through eosinophil-derived IL-




Figure 28: Eosinophils are the major producers of IL-4 in myocarditis 
Mice were analyzed at day 21 of EAM. A) Gating of IL-4 expressing (GFP+) cells out of viable, CD45+ cells in 
the heart of 4get mice (IL-4-GFP reporter mice). B) Frequency of cell types out of heart-infiltrating or splenic 
GFP+ cells (average of 3 mice). C) Gating of eosinophils out of viable, CD45+ cells and GFP expression in 
eosinophils from WT and 4get mice. D) Frequency of GFP+ cells among different heart-infiltrating cell types. 




Figure 29: Eosinophil-derived IL-4 promotes DCMi 
A, D) Heart function was assessed by echocardiography on day 45 of EAM in the indicated strains. A) Data 
are representative of 3 independent experiments with 4-8 mice/group. B, C) Infiltrating cells in the ventricle 
were quantified by flow cytometry on day 21 of EAM. Data are from one experiment with 4-5 mice/group. 
D) Data are from one experiment with 9-10 mice/group. Groups were compared by one-way ANOVA 
followed by Tukey’s multiple comparisons test for all groups against each other (A) or by t-test (B-D). 





Figure 30: EoCrewt/tgIL-4/13fl/fl mice develop fibrosis to the same extent as WT mice but show altered 
tissue remodeling similar to ΔdblGATA1 mice 
Mice were analyzed at day 45 of EAM. A) Heart sections were stained with Masson’s trichrome and are 
shown representatively for all indicated mouse strains. Mice from different experiments are shown. Grey 
scale bars: 1mm, black scale bars: 100µm. B, C) The extent of fibrosis was determined by scoring fibrotic 
areas on histological sections. Groups were compared by Mann-Whitney test (no significant differences). 
D) Eosinophil frequency in blood was determined by flow cytometry. E) Gene expression in heart 
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homogenates was analyzed by qPCR. D, E) Groups were compared by one-way ANOVA followed by Tukey’s 
multiple comparisons test. Asterisk indicate significance: *p<0.05, **p<0.01, ***p<0.001. 
Discussion 
In this study, we demonstrated that eosinophils are necessary for the progression of autoimmune 
myocarditis to DCMi. Mice lacking eosinophils developed myocardial inflammation similar to WT mice 
following EAM induction but did not develop DCMi and showed no signs of heart failure. Eosinophils 
accounted for 1-3% of heart-infiltrating CD45+ cells in WT mice. While their absence did not prevent 
myocarditis or affect its severity, it had a prominent effect on DCMi development. This shows that the 
severity of myocarditis does not necessarily determine the long-term disease outcome, but specific 
infiltrating cell types are decisive for disease progression.  
IL-5Tg mice can develop spontaneous cardiac enlargement and eosinophil infiltration at an unknown rate195. 
EAM induction results in myocarditis in nearly all mice, making it a much more reliable model and more 
feasible to study because of the defined onset. EAM in IL-5Tg mice is a model of eosinophilic myocarditis 
with hypereosinophilia. HES patients frequently develop endomyocardial thrombi which are thought to 
result in endomyocarditis and endomyocardial fibrosis33, 182. We rarely observed intra-atrial or 
intraventricular thrombi and no signs of endocarditis in IL-5Tg mice following EAM induction. HES patients 
can also develop eosinophilic myocarditis or pericarditis33, 182. In IL-5Tg mice, inflammation was primarily 
located in the ventricular myocard and atria; pericarditis was mild. Most notably, IL-5Tg mice develop 
extensive eosinophil infiltration of the myocard associated with a loss in EF, which is also observed in HES 
patients. 
We previously reported on acutely fatal eosinophilic myocarditis developing in IFNγ-/-IL-17A-/- mice 189. 
Induction of EAM in IL-5Tg mice offers a second model of eosinophilic myocarditis with several differences: 
1) IL-5Tg mice have hypereosinophilia, while IFNγ-/-IL-17A-/- mice have normal peripheral blood eosinophil 
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levels. 2) Eosinophils reach over 60% of heart-infiltrating cells in IL-5Tg mice, and about 30% in IFNγ-/-IL-17A-
/- mice. 3) Eosinophil migration to the heart depends on the eotaxin-CCR3 pathway in IFNγ-/-IL-17A-/- mice74. 
For IL-5Tg mice, the mediators of eosinophil trafficking are not known. Eotaxin expression is comparable to 
WT mice in the ventricles and slightly increased in the atria. 4) The severity of myocardial inflammation is 
moderate in IL-5Tg mice while IFNγ-/-IL-17A-/- mice develop massive inflammation that encompasses almost 
the entire myocardium and likely causes fatality in these mice. IL-5Tg mice rarely died after EAM induction. 
Severe atrial inflammation is present in both strains. Importantly, both strains develop heart failure that is 
rescued by ablation of eosinophils. This confirms a crucial role for eosinophils in driving DCMi.  
Severe atrial inflammation and fibrosis were unique features in IL-5Tg mice. Severe atrial fibrosis may have 
caused atrial fibrillation or arrhythmias in IL-5Tg mice. We noted atrial involvement in 2/3 eosinophilic 
myocarditis patients described here. A recent case series found that 8 of 9 patients with eosinophilic 
myocarditis had enlargement of the atria243. Another study characterized 6 patients with isolated atrial 
giant cell myocarditis showing atrial fibrillation, atrial wall thickening, atrial enlargement, and marked atrial 
inflammation168. Similar observations were made in case reports of giant cell myocarditis 244 and 
eosinophilic myocarditis34, 245, 246. Eosinophilic myocarditis has also been identified as a cause of 
atrioventricular block in one patient247. This suggests that atrial inflammation and/or fibrosis are also a 
feature of some eosinophilic myocarditis patients. Future studies should explore what determines atrial 
involvement in eosinophilic myocarditis and assess possible pro-arrhythmogenic effects of such 
inflammation. 
The exacerbated heart failure in IL-5Tg mice was due to the high numbers of eosinophils. IL-5 was not 
directly responsible for this phenotype because IL-5TgΔdblGATA1 with high serum IL-5 but no eosinophils 
were protected from DCMi and IL-5-/- mice exhibited DCMi comparable to WT mice. This clearly 
demonstrated that the role of IL-5 was limited to promoting eosinophilia. Eosinophils, in turn, were 
responsible for the DCMi phenotype and increasing numbers resulted in more severe DCMi. As a result of 
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the size difference between atria and ventricles, most cardiac eosinophils located to the ventricles despite 
more severe inflammation in the atria. It is unclear whether eosinophil infiltration in the atria or ventricles 
were responsible for the severe DCMi observed in these mice. Because of the rarity of eosinophilic 
myocarditis, it is not known what percentage of eosinophilic myocarditis patients progress to DCMi. In a 
study on the survival of 112 biopsy-proven myocarditis patients, 4 out of 7 patients with eosinophilic 
myocarditis underwent cardiac transplantation within 1 year of diagnosis113, suggesting that transplant-free 
survival may be particularly poor among these patients. In one series of eosinophilic myocarditis patients, 
EF was impaired in all 5 patients and severely impaired in 2 patients268. More studies will be necessary to 
determine if eosinophilic myocarditis is associated with progression to DCMi in patients.  
In previous studies, we showed that IL-17A is another driver of DCMi197, 240. In the absence of IL-17A, mice 
are protected from DCMi and show markedly reduced levels of cardiac fibrosis. Eosinophils drive DCMi 
through a distinct mechanism. Lack of eosinophils or eosinophil-derived IL-4 did not affect fibrosis or 
collagen levels in the heart but rather affected expression of tissue remodeling-associated genes. In this 
paper, we demonstrate that mice can develop cardiac fibrosis but still retain a high ejection fraction. 
Therefore, the level of fibrosis is not a necessary negative regulator of cardiac function. It is possible that 
both increased collagen production induced by IL-17A and tissue remodeling by matrix metalloproteinases 
stimulated by eosinophils are necessary to drive progression of myocarditis to DCMi. Another conceivable 
explanation would be a direct link between Th17 responses and eosinophils as it was suggested in recent 
studies. The Th17 effector cytokine GM-CSF enhances eosinophilopoiesis, induces cytokine secretion, and 
promotes survival269, 270.  
We tested numerous hypotheses regarding the mechanism by which eosinophils promote DCMi: direct 
cytotoxic effects, activation of other immune cell types (T cells or dendritic cells), effects on antibody 
production, and eosinophil peroxidase-driven effects. None of these were supported by the data. However, 
eosinophils in the heart showed an activated phenotype with formation of vesiculo-tubular structures in 
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the cytoplasm without a large extent of degranulation. We hypothesized that eosinophils may be releasing 
specific mediators to promote DCMi.  
We showed that eosinophil-derived IL-4 is critical for progression of myocarditis to DCMi. Several previous 
studies have uncovered a role for eosinophils and IL-4 in physiological processes including tissue 
regeneration, differentiation of beige fat, and glucose homeostasis264-267. Here, we report a pathogenic role 
for eosinophil-derived IL-4. By specifically deleting IL-4 in eosinophils, we demonstrate that eosinophils are 
indeed the source of IL-4 required for DCMi development. This does not exclude the possibility of additional 
eosinophil-derived mediators contributing to heart failure.  
While eosinophils are not the only cells known to produce IL-4, other cell types are much less likely to be 
the main source of IL-4 in the heart. Basophils can produce IL-4271, 272 and can be affected by the ΔdblGATA1 
mutation that prevents eosinophil development273. However, basophils comprised less than 2% of all IL-4-
producing cells in myocarditis and there was no difference in the frequency of heart-infiltrating basophils 
between WT and ΔdblGATA1 mice. While T cells can also produce IL-4, they represented less than 10% of 
all IL-4 expressing heart-infiltrating cells during myocarditis.  
Our studies also provide insight into the opposing effects of IL-4 and IL-13 in myocarditis. We previously 
published that IL-13 is protective in myocarditis and DCMi239. IL-13-deficient mice develop severe 
myocarditis and rapidly progress to heart failure. In contrast, IL-4-deficient mice exhibit myocarditis of 
similar severity as WT mice239 but were completely protected from DCMi. While both are hallmark cytokines 
of a type 2 immune response, the sources of these cytokines are different. IL-4 is mostly expressed by 
eosinophils and to a lesser extent by CD4+ T cells. The major source of IL-13 is likely lymphoid: T cells and 
innate lymphoid cells. IL-13 protects against myocarditis through multiple effects on monocytes and 
macrophages239. IL-4 may act on other target cells. Given these different roles of IL-4 and IL-13 in 
myocarditis, it is unlikely that the absence of IL-13 in EoCrewt/tgIL-4/13fl/fl mice is responsible for the 
observed protective effect.  
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Currently, no drugs are available to arrest or delay development of DCMi, or to improve long-term survival 
of DCMi patients. Our results uncovered a new pathway critically involved in the progression of myocarditis 
to DCMi. Preventing eosinophilia or blocking IL-4 in patients with myocarditis may halt disease progression 






Chapter 5: Eosinophils in autoimmune diseases 
This chapter is under review at Frontiers in Immunology as a review article: 
Diny NL, Rose NR, Čiháková D. Eosinophils in autoimmune diseases. 
Summary 
Eosinophils are multifunctional granulocytes that contribute to initiation and modulation of inflammation. 
Their role in asthma and parasitic infections has long been recognized. Growing evidence now reveals a role 
for eosinophils in autoimmune diseases. In this review, we summarize the function of eosinophils in 
inflammatory bowel diseases, neuromyelitis optica, bullous pemphigoid, autoimmune myocarditis, primary 
biliary cirrhosis, eosinophilic granulomatosis with polyangiitis, and other autoimmune diseases. Clinical 
studies, eosinophil-targeted therapies and experimental models have contributed to our understanding of 
the regulation and function of eosinophils in these diseases. By examining the role of eosinophils in 
autoimmune diseases of different organs we can identify common pathogenic mechanisms. These include 
degranulation of cytotoxic granule proteins, induction of antibody-dependent cell-mediated cytotoxicity, 
release of proteases degrading extracellular matrix, immune modulation through cytokines, antigen 
presentation, and pro-thrombotic functions. The association of eosinophilic diseases with autoimmune 
diseases is also examined, showing a possible increase in autoimmune diseases in patients with eosinophilic 
esophagitis, hypereosinophilic syndrome and non-allergic asthma. Finally, we summarize key future 
research needs. 
Introduction 
Activation of innate immune cells by pathogen-associated molecular patterns and antigen presentation by 
dendritic cells can result in priming of autoreactive T and B cells and set off an adaptive immune response 
against self-antigens274-276. Possible roles for innate immune cells exist not only in the initiation stage of 
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autoimmune diseases, but also in the modulation and propagation of inflammation and tissue destruction. 
Such roles have been proposed for neutrophils277, natural killer cells278, 279, macrophages280, dendritic 
cells281, 282, innate lymphoid cells283, and mast cells284. Eosinophils have been recognized as part of the 
inflammatory infiltrate in several organ-specific autoimmune diseases, but their potential role in 
autoimmune diseases has not been addressed comprehensively.  
The aim of this review is to synthesize the role of eosinophils in different autoimmune diseases and explore 
potential unifying effector mechanisms. We also address the association of autoimmune diseases with 
eosinophil-associated disease like asthma and eosinophilic esophagitis. 
Possible eosinophil effector functions in autoimmune diseases 
Eosinophils are extremely versatile effector cells that damage tissues or modulate the activity of other 
immune and stromal cells (see Chapter 1). One could envision many of these effector functions playing a 
role in the context of autoimmune diseases as well (Figure 31). Damage of tissue and cells is a feature of 
many organ-specific autoimmune diseases. Eosinophils are well known for their strong cytotoxic properties, 
mediated mostly through granule proteins. This could contribute to organ destruction in autoimmune 
inflammation.  
The ability of eosinophils to bind antibodies and consequently degranulate and kill cells links the adaptive 
autoimmune response to eosinophil effector functions. Eosinophils express complement receptors285 and 
Fc-receptors (FcαR, FcγRI-III, FcεRI-II) either constitutively or under inflammatory conditions286-289. As a 
result, they are capable of antibody-dependent cellular cytotoxicity to parasites and mammalian targets290-
292. In autoimmune diseases, eosinophils may kill host cells bound by autoantibodies. 
Eosinophils also interact with stromal cells. Actively degranulating eosinophils are frequently found in areas 
of fibrogenesis, suggesting a potential profibrotic role44, 293-295. Granule proteins and eosinophil-derived 
TGFβ1 were demonstrated to affect tissue remodeling and fibrosis. Eosinophils can promote fibroblast 
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proliferation296-298, proteoglycan accumulation299, matrix metalloproteinase and TGFβ expression, and 
extracellular matrix protein synthesis300. These profibrotic functions of eosinophils may add to tissue 
dysfunction in autoimmune diseases. 
In chronic inflammatory conditions, eosinophils preferentially locate to nerves211, 301-303. This interaction 
results in activation of eosinophils304-306, nerve damage307, 308, altered nerve growth309, 310, neuropeptide 
release311. Contact between eosinophils and nerves has functional consequences. For example, it is a cause 
of airway hypersensitivity in asthma88, 312.  
Eosinophils can form extracellular DNA traps by quickly releasing mitochondrial DNA and granule 
proteins313. These structures bind and kill pathogens and contribute to tissue injury in inflammatory 
conditions314. DNA extracellular traps have been described in allergic asthma315, drug hypersensitivity 
reactions, and allergic contact dermatitis316. Eosinophils may initiate or perpetuate inflammation by 
releasing cytokines and chemokines and by interacting with other innate immune cells. For example, 
eosinophils release MBP, IL-9, stem cell factor, or nerve growth factor, which affect mast cell maturation, 
survival, and histamine release317-320.  
Eosinophils can also influence the adaptive immune response. They are capable antigen presenting cells 
that upregulate MHCII and co-stimulatory molecules in the context of parasitic infection or allergic 
asthma321-323. Moreover, eosinophils migrate to draining lymph nodes324 and in vitro experiments have 
demonstrated their ability to present antigen to and activate T cells325-327. Through antigen presentation, 
eosinophils may be involved in the initiation of autoimmune responses.  
Eosinophil granules contain numerous cytokines such as IL-4, IL-13, IL-25, TGFβ, IL-10, or IDO81, which 
suggests an ability to affect T cell differentiation. Eosinophils were shown to suppress Th1/Th17 
differentiation248 or activate Th2 responses in draining lymph nodes328. In addition, they modulate dendritic 
cell activity, thereby indirectly affecting T cell differentiation329. Eosinophils also shape the humoral immune 
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response. In the bone marrow, eosinophils stimulate plasma cell survival by producing IL-6 and APRIL251 and 
in the intestine, they promote class-switching to IgA249, 250. These properties enable eosinophils to shape 
the adaptive immune response in autoimmune diseases. 
Eosinophils may also fulfill immune regulatory and protective functions. Eosinophil-derived mediators like 
TGFβ and TGFα330, platelet derived growth factor331, vascular endothelial growth factor332, and fibroblast 
growth factor333 can all contribute to tissue repair and angiogenesis but can also promote maladaptive 
fibrosis in chronic autoimmune inflammation. IL-4 released from eosinophils was shown to play a role in 
liver265 and muscle267 regeneration. Whether eosinophils contribute to tissue repair or tissue damage is 
likely context and disease dependent.  
 
Figure 31: Possible eosinophil effector mechanisms in autoimmune diseases 
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Role of eosinophils in autoimmune diseases 
Bullous pemphigoid 
Bullous pemphigoid is a blistering disease of the skin with a well-established autoimmune etiology334. 
Autoantibodies bind to hemidesmosomal proteins BP180 and BP230 at the dermal-epidermal junction and 
other extracellular matrix proteins335-340. Hemidesmosomes are part of the complexes that anchor the 
cytoskeleton of basal keratinocytes to the dermis341. Autoantibody binding triggers complement activation, 
recruitment of immune cells, and release of proteases. This results in tissue damage and blistering342-345. 
Together with mast cells and neutrophils, eosinophils infiltrate the dermal-epidermal junction and are 
thought to play a key role in bullous pemphigoid346-348. Increased numbers of peripheral blood eosinophils 
has long been recognized as a characteristic of bullous pemphigoid patients349, 350. A positive correlation 
between blood eosinophil numbers and disease severity has been observed in some reports351, 352 but not 
others353. Eosinophilia in bullous pemphigoid patients is likely caused by increased levels of IL-5, which can 
be detected at high levels in the serum and blister fluid354, 355. Keratinocytes in the blisters express eotaxin-
1, which directs eosinophil infiltration354, 356. Eotaxin-1 expression is positively correlated with the number 
of infiltrating eosinophils in blisters. Eosinophil localization to the basement membrane zone is 
autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid348. 
Eosinophils from blisters release IL-6, IL-8, and IL-1β and show an activated phenotype with high CD11b 
expression357. Blister eosinophils also underwent apoptosis more readily compared to eosinophils from 
healthy donors357. 
Several mechanisms by which eosinophils (and other granulocytes) contribute to lesion formation have 
been identified. Eosinophils in lesional skin were shown to degranulate and granule proteins are deposited 
in blisters346, 358. The eosinophil granule protein ECP can readily be detected in serum and blister fluid of 
bullous pemphigoid patients353. However, it is not clear if granule proteins contribute to tissue damage. 
Eosinophils and neutrophils have been shown to release proteases, matrix metalloproteinase 9 (MMP9) 
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and neutrophil elastase, in lesional biopsies and blister fluid. These proteases can degrade extracellular 
matrix proteins and BP180, which contributes to dermal-epidermal separation and blister formation359-361. 
Blister formation also depends on autoantibodies362, which are of the IgG1, IgG4, and IgE subtype363, 364. 
Recently, eosinophils from bullous pemphigoid patients were shown to express the high affinity IgE 
receptor FcεRIα365, which may trigger eosinophil activation by IgE autoantibodies. Additional evidence for 
a pathogenic role for eosinophils comes from a case report of a patient with hypereosinophilic syndrome 
and bullous pemphigoid who was treated with imatinib (a tyrosine kinase inhibitor). In response to imatinib 
both conditions resolved and his eosinophil count normalized366. 
Taken together, there is strong evidence from patient studies, in vitro experiments, and animal models for 
a pathogenic role of eosinophils in bullous pemphigoid. In addition to the mouse model of passive antibody 
transfer, which reproduces blister formation but not eosinophil infiltration367, a new model with genetically 
modified mice has been established368. Mice with a deletion in the BP180 (Collagen XVII) gene 
spontaneously develop eosinophilia, blister formation, itch and eosinophil infiltration into the skin lesions. 
This new model could be used to test for the requirement and pathologic role of eosinophils (and eosinophil 
products) in future studies. Novel eosinophil-specific drugs may also help to clarify the role of eosinophils 
in bullous pemphigoid. Trials of bertilimumab, an anti-eotaxin-1 antibody, and mepolizumab, an anti-IL-5 
antibody, are currently ongoing (ClinicalTrials.gov identifiers: NCT02226146, NCT01705795). 
Inflammatory Bowel diseases 
The etiology of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis is not fully 
understood. Evidence for the involvement of autoimmune processes exists for both369, 370. Both diseases 
are associated with other autoimmune diseases, characterized by lymphocytic infiltration, and respond to 
corticosteroid treatment. Neither of the diseases are associated with HLA haplotypes. Patients with 
ulcerative colitis carry autoantibodies against colonic epithelial cells and often perinuclear anti-neutrophilic 
cytoplasmic antibodies. Specific autoantibodies have not been found in Crohn’s disease patients. The 
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evidence for autoimmunity is stronger in ulcerative colitis than in Crohn’s disease. Here, we will discuss the 
role of eosinophils in both diseases with a focus on ulcerative colitis.  
Eosinophils have long been recognized as a prominent feature of the infiltrate in inflammatory bowel 
diseases371-375. Eosinophil numbers in the colon are substantially increased in inflammatory bowel disease 
patients and display an activated phenotype375-378. The number of infiltrating eosinophils is positively 
correlated with disease severity in ulcerative colitis and Crohn’s disease73, 379-382. In mouse models, the 
absence of eosinophils dramatically reduces disease severity. In the model of DSS-induced colitis, two 
different strains of eosinophil-deficient mice were protected compared to controls73, 383. Depletion of 
eosinophils in a model of colitis due to Helicobacter hepaticus infection also reduced disease severity269. 
Similarly, in a model of TNBS-induced colitis, eosinophil-deficient mice fared better, while hypereosinophilic 
mice developed more severe disease384. 
Eosinophil migration into the colon mucosa occurs in response to eotaxins. Patients with inflammatory 
bowel diseases have elevated serum eotaxin-1 levels379, 385, 386, which correlates positively with disease 
activity379, 385. Tissue expression of eotaxin-1, and to a lesser extent eotaxin-2, is increased in ulcerative 
colitis patients and positively correlated with the number of infiltrating eosinophils and histopathologic 
disease severity73, 379. Another study found increased expression of all 3 eotaxins and IL-5 in ulcerative 
colitis, but only eotaxin-1 correlated with eosinophil numbers387. The relative significance of eotaxin-2 and 
-3 is less clear. Eotaxin-3 was found to be increased in active lesions in ulcerative colitis and to a lesser 
extent in Crohn’s disease204. Gene polymorphisms in eotaxin-2 are associated with ulcerative colitis388. This 
suggests that all eotaxins may contribute to eosinophil trafficking. The cellular source of eotaxin-1 was 
identified as CD68+ macrophages and epithelial cells73 or as CD14+ mononuclear cells387. Colonic 
myofibroblasts express eotaxin-3, which is increased in response to IL-4 and IL-13204. In the mouse model 
of DSS-induced colitis, eotaxin-1 and -2 expression in the colon is increased and deficiency in eotaxin-1, but 
not in eotaxin-2, decreases eosinophil infiltration. This demonstrates that eotaxin-1 is the major 
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chemoattractant for eosinophils in experimental colitis73, 256. In this mouse model, macrophages are the 
major eotaxin-1 producing cell type73, 389. The increased expression of eotaxins, particularly eotaxin-1, in 
inflammatory bowel diseases shows that eosinophils are specifically recruited to the site of inflammation.  
Electron microscopy and immunohistochemistry of colonic biopsies show degranulation of eosinophils378, 
390, 391. Eosinophil granule proteins are also found in the feces377, 392, gut perfusates393, and gut lavage 
fluids394 from patients with ulcerative colitis and Crohn’s disease. Eosinophil granule proteins in serum or 
intestine are positively correlated with disease activity in ulcerative colitis73, 377, 382, 395, 396. Polymorphisms in 
the genes of ECP and EPX are associated with inflammatory bowel diseases397. These findings suggest a 
pathogenic role of eosinophil granule proteins in inflammatory bowel diseases. In one study, however, 
eosinophil activation was observed during the remission phase398. EPX is pathogenic in mouse models of 
DSS- and Helicobacter hepaticus-induced colitis. Genetic deficiency or inhibition of EPX reduced disease 
severity256, 269. 
Several pathogenic functions of eosinophils have been suggested in recent years. Eosinophils were found 
to increase mucosal barrier permeability in ulcerative colitis by releasing MBP399 or corticotropin-releasing 
factor400. IL-22 is increased in patients with ulcerative colitis or Crohn’s disease401, 402 and animal studies 
showed that it is crucial to restore epithelial homeostasis403. IL-22 induces antimicrobial peptides, mucus 
production and epithelial tight junctions404. Recently, eosinophils were identified as the main source of IL-
22 binding protein, inhibiting the protective actions of IL-22 in DSS-induced experimental colitis and in 
patients with inflammatory bowel disease405. In another study, eosinophils were found to localize to nerves 
in the colonic mucosa in ulcerative colitis and Crohn’s disease211. Th17 responses have been implicated in 
inflammatory bowel diseases406. A possible link between the downstream effector of Th17 responses, GM-
CSF, and eosinophils was found recently. GM-CSF enhances eosinophilopoiesis, induces cytokine secretion 
from eosinophils, and promotes eosinophil survival269, 270. 
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In summary, tissue eosinophils are increased in patients with inflammatory bowel diseases, are associated 
with disease severity, and are specifically recruited through eotaxin-1. Eosinophils likely contribute to the 
disease process by releasing granule proteins (EPX) or other mediators that affect the intestinal barrier. 
Thus, there is strong evidence for a pathogenic role of eosinophils in inflammatory bowel diseases, 
particularly in ulcerative colitis. 
Eosinophilic granulomatosis with polyangiitis 
Eosinophilic granulomatosis with polyangiitis (EGPA) was first described by Churg and Strauss in 1951407. 
The disease progresses through 3 overlapping phases: adult-onset asthma, peripheral and tissue 
eosinophilia, and necrotizing vasculitis with tissue infiltration of eosinophils163, 408, 409. EGPA is an idiopathic 
type of small vessel vasculitis and is also part of the hypereosinophilic syndromes410. It is associated with 
HLA and IL-10 polymorphisms411. About 40% of EGPA patients have perinuclear anti-neutrophilic 
cytoplasmic (ANCA) antibodies against myeloperoxidase (MPO), resulting in the classification of EGPA as an 
ANCA-associated vasculitis163, 409. The presence or absence of ANCA in EGPA may indicate 2 clinical subtypes 
with different organ involvement. ANCA-positive patients have more frequent vasculitis and 
glomerulonephritis, whereas ANCA-negative patients have more frequent heart and lung involvement32, 35.  
Blood and tissue eosinophilia are diagnostic criteria for EGPA, yet little is known about the pathogenic role 
of eosinophils in this disease409. One reason for the absence of mechanistic data is the lack of suitable animal 
models. The transfer of MPO-positive human serum to mice causes vasculitis, but the eosinophilic 
component is missing412. Therefore, all knowledge about the role of eosinophils in EGPA comes from patient 
studies. An increased eosinophil count during active disease is associated with increased Th2 cytokines IL-
5 in serum413, 414 and increased production of IL-4, IL-5, and IL-13 by T cells415, 416. CCL17, a chemokine that 
recruits Th2 cells into tissues, is increased in the serum and in biopsies of EGPA patients and is positively 




Blood eosinophils in EGPA show an activated phenotype expressing high levels of CD69 and CD11b414, 418. 
Moreover, they express IL-25, a cytokine that increases IL-4, -5, and -13 release from T cells. Serum IL-25 is 
increased in patients with active EGPA compared to inactive disease, or healthy controls. It is also 
detectable in eosinophils from lesional biopsies. T cells in these biopsies and in the blood express the IL-25 
receptor IL-17RB419. This suggests a feed forward loop between eosinophils and Th2 cells in EGPA.  
Neuropathy is a common symptom of EGPA32. Interestingly, different mechanisms lead to nerve damage 
depending on the presence or absence of MPO-ANCA. In patients with autoantibodies, MPO-ANCA-induced 
necrotizing vasculitis results in ischemic damage to the nerves420-423. In the absence of autoantibodies, 
massive eosinophil infiltration into the epineurium and occasionally endoneurium is observed. These 
eosinophils are degranulating and cytotoxic to nerves423, 424. Sometimes eosinophils form part of the 
inflammatory infiltrate surrounding necrotizing vessels423, 425, 426. This may accelerate damage of blood 
vessels because eosinophils were shown to be directly cytotoxic to endothelial cells in vitro84, 427. This 
damage may be mediated by ECP, which is deposited on endothelial surfaces in patients with eosinophilic 
endomyocarditis428-430 or by MBP, which is cytotoxic in vitro84. 
Eosinophil chemotaxis into affected tissues in EGPA patients occurs in response to eotaxin-3. Serum levels 
of eotaxin-3 are substantially higher in EGPA patients with active disease compared to those with inactive 
disease, healthy controls, or patients with other eosinophil-associated diseases212, 431. In contrast, there is 
no increase in serum eotaxin-1 or -2212. Eotaxin-3 is also readily detected in biopsies of affected tissues from 
EGPA patients212 . Eotaxin-3 localizes to endothelial cells of small vessels, smooth muscle cells of small 
arterioles, the perineurium of the sural nerve, and the respiratory epithelium of the nose. An analysis of 
single nucleotide polymorphisms in the eotaxin-3 gene in 161 EGPA patients found no significant 
associations431, suggesting that eotaxin-3 polymorphisms may not be causal in EGPA. 
The strongest evidence for a pathogenic role of eosinophils in EGPA comes from novel biological treatments 
that target IL-5 and thereby drastically reduce eosinophil levels. Two open-label trials with the anti-IL-5 
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antibody mepolizumab demonstrated its efficacy as a steroid-sparing agent and its ability to induce 
remission over 9 months432-434. Upon termination of mepolizumab treatment the majority of patients 
developed relapses. In one trial, eosinophil count and serum ECP were strongly correlated with disease 
activity434. A double-blind randomized placebo-controlled trial of mepolizumab in EGPA is currently ongoing 
(ClinicalTrials.gov identifier: NCT02020889). 
Several key findings amount to moderate evidence for a pathogenic role of eosinophils in EGPA. 1) The 
number of eosinophils and serum ECP correlate with disease severity. 2) Eosinophil infiltration and 
degranulation in tissues causes organ damage. 3) A potential feed-forward loop between Th2 cells and 
eosinophils may propagate disease. 4) IL-5 targeted therapies showed beneficial effects.  
Eosinophilic myocarditis 
Myocarditis is the inflammation of the heart muscle with or without damage or necrosis of adjacent 
myocytes in the absence of an ischemic event1. A wide range of causes from viral, bacterial and parasitic 
infections to toxic effects of drugs or hypersensitivity reactions can cause myocarditis and in many cases 
the etiology is unknown6. Autoimmune processes often play a role either causally or as post-infection 
autoimmunity: autoantibodies against cardiac antigens are present in the majority of myocarditis patients, 
myocarditis is associated with other autoimmune diseases, and some patients benefit from 
immunosuppressive treatment9, 12. Animal models provide further evidence for autoimmune mechanisms. 
Cardiac autoantibodies induce disease in rats, and immunization with cardiac myosin peptide in adjuvants 
induces experimental autoimmune myocarditis (EAM) in mice12.  
Eosinophils form a major part of the inflammatory infiltrate in subtypes of myocarditis, namely in 
eosinophilic myocarditis and giant cell myocarditis. These subtypes are usually idiopathic. Eosinophilic 
myocarditis is associated with hypereosinophilic syndrome and EGPA but it can also develop in the absence 
of eosinophilia. About one third of EGPA patients and 20-50% of HES patients develop cardiovascular 
manifestations32-35, 164, 182. Myocarditis is more frequent in ANCA-negative EGPA patients32, 164. Parasitic 
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infections and hypersensitivity reactions to drugs are other potential causes of eosinophilic myocarditis14, 
24. Giant cell myocarditis and eosinophilic myocarditis are usually treated with strong immunosuppressive 
agents. 
Eosinophils likely play a pathogenic role in the heart34, 40, 185. Eosinophil granule proteins are deposited in 
the myocardium during eosinophilic myocarditis and may be cytotoxic to cardiomyocytes39, 43, 44, 186. 
Eosinophils have also been proposed to activate cardiac mast cells435, or release pro-thrombotic tissue 
factor46. In HES, eosinophils are thought to damage the endocardium, which results in thrombosis and 
endocarditis and eventually leads to endomyocardial fibrosis and valvular complications33, 182.  
Animal studies further strengthen the evidence that eosinophils contribute to pathology and mortality in 
eosinophilic myocarditis. Hypereosinophilic mice with transgenic expression of IL-5 (IL-5Tg) spontaneously 
develop eosinophilic myocarditis at a low frequency195. We found that induction of experimental 
autoimmune myocarditis (EAM) in these IL-5Tg mice reliably induces eosinophilic myocarditis with over 
60% of the heart-infiltrating cells being eosinophils (see Chapter 4). 
Induction of EAM in A/J mice causes myocarditis with numerous infiltrating eosinophils436. Blockade of IL-4 
in this model reduces eosinophil infiltration and disease severity436. Induction of EAM in BALB/c mice that 
lack IFNγ and IL-17A (IFNγ-/-IL-17A-/-) results in severe eosinophilic myocarditis with about 50% fatality by 
day 21189. Ablation of eosinophils in these mice improved survival. In another model, natural killer cell 
depletion resulted in increased eosinophil infiltration in the heart and aggravated myocarditis. In 
eosinophil-deficient mice, however, natural killer cell depletion did not increase disease severity187. These 
results show that eosinophils are pathogenic in myocarditis.  
A major burden of myocarditis lies in the sequela inflammatory dilated cardiomyopathy (DCM), which is the 
major cause of heart failure in patients under 40 years of age and has a poor 5-year survival rate of less 
than 50%138, 173. It is not known at what rate eosinophilic myocarditis patients progress to DCM or how this 
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rate compares to other myocarditis subtypes. Using the EAM model, we found that eosinophil-deficient 
mice are protected from DCM following myocarditis, while hypereosinophilic mice developed more severe 
DCM. This process was dependent on eosinophil-derived IL-4 (see Chapter 4). This suggests that eosinophils 
drive the chronic disease that ensues myocarditis. 
Little is known about the mediators that induce eosinophil infiltration into the heart. We found increased 
expression of eotaxin-1 and eotaxin-3 in endomyocardial biopsies from patients with eosinophilic 
myocarditis compared to chronic lymphocytic myocarditis74. In the eosinophilic myocarditis mouse model 
of EAM in IFNγ-/-IL-17A-/- mice, cardiac expression of eotaxin-1 and -2 is highly increased compared to naïve 
mice or WT controls74, 189. In this model, the eotaxin-CCR3 pathway is necessary for eosinophil trafficking to 
the heart during myocarditis74. 
In summary, there is substantial evidence that eosinophils play a pathogenic role in myocarditis during the 
acute and chronic stage. Several studies in animal models offered mechanistic insight into how eosinophils 
contribute to myocarditis. It will be interesting to see if eosinophil-targeted therapies in patients with HES 
or EGPA will reduce the incidence of eosinophilic myocarditis in this high-risk group.  
Neuromyelitis optica 
Neuromyelitis optica (NMO) is a demyelinating disease of the central nervous system that usually affects 
the optic nerve and spinal cord. Lesions are necrotic, cavitary, and infiltrated with macrophages and 
granulocytes. NMO is an autoimmune disease. Anti-aquaporin 4 (AQP4) autoantibodies are present in the 
majority of patients. These pathogenic antibodies are highly specific for NMO and are one of the features 
that distinguish it from multiple sclerosis. NMO patients often carry multiple other autoantibodies and 
there is a strong association with other autoimmune diseases. Moreover, NMO is much more common in 
women than men437. 
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NMO has only recently been distinguished from multiple sclerosis with eosinophil infiltration being one of 
the distinctive features438. The first description of eosinophil infiltration in NMO lesions was by Lucchinetti 
and colleagues in 2002. In analyzing lesions from NMO patient autopsies, they found eosinophil infiltration 
in early active lesions439. Eosinophils infiltration is located meningeal and perivascular in spinal cord lesions. 
Both intact and degranulating eosinophils are found439. Since this original observation, multiple studies have 
described eosinophil infiltration in the spinal cord, optic nerve440, brainstem441, 442, and cerebrospinal 
fluid443. Another study found that the cerebrospinal fluid from patients with NMO contains higher levels of 
eotaxin-2, eotaxin-3, and ECP compared to healthy controls or multiple sclerosis patients. In addition, 
stimulation of cerebrospinal fluid cells with myelin oligodendrocyte glycoprotein results in increased IL-5 
production in NMO compared to controls444. Together, these studies clearly establish that eosinophils 
infiltrate and degranulate in NMO lesions, which suggests a pathogenic role for eosinophils. 
A recent elegant study used in vitro experiments and a mouse model to determine the role of eosinophils 
in NMO445. Bone marrow-derived eosinophils exhibit antibody-dependent cellular cytotoxicity (ADCC) when 
co-cultured with a cell line expressing AQP4 in the presence of anti-AQP4. Similar effects of eosinophils are 
observed on spinal cord slide cultures. Stimulation of eosinophils with platelet activating factor, which 
induces release of EPX, results in damage to spinal cord slice cultures independent of anti-AQP4 antibody. 
The authors developed a mouse model of NMO by continuously infusing anti-AQP4 antibodies and human 
complement intracerebrally for 3 days. In this model, depletion of neutrophils, eosinophils or both reduces 
pathology. Likewise, eosinophil-deficient mice have less severe lesions. Induction of disease in 
hypereosinophilic mice results in more severe lesions with increased eosinophil and neutrophil 
infiltration445. This clearly established a pathogenic role for eosinophils in NMO and highlights mechanisms 
(ADCC and degranulation) by which eosinophils can damage neural tissues.  
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Primary biliary cirrhosis 
Primary biliary cirrhosis is a chronic disease of the small intrahepatic bile ducts that eventually leads to 
cirrhosis. It shows several hallmarks of an autoimmune disease: highly specific anti-mitochondrial 
autoantibodies, association with other autoimmune diseases, a female to male ratio of 10:1, and a strong 
genetic component446. Histologically, damaged biliary epithelial cells and infiltration of the portal area with 
plasma cells, T cells, NK cells, macrophages, neutrophils, and eosinophils are visible446, 447. Cytokine 
expression in the liver of primary biliary cirrhosis patients is similarly mixed. Compared to other liver 
diseases, increased hepatic expression of IL-5, IL-6, IFNγ, TGFβ, and IL-2 has been noted448, 449. Recent 
studies also identified key Th1 and Th17 cytokines in the liver 450 and on blood cells451, and a decreased T 
regulatory to Th17 cell balance in peripheral blood cells452.  
Patients with primary biliary cirrhosis have a higher frequency and increased absolute numbers of 
eosinophils in peripheral blood and the liver, particularly around damaged bile ducts453-456. Eosinophil 
infiltration is higher in the early stages of the disease (stages I-II versus III-IV)454, 456. Increased eosinophil 
infiltration was positively associated with liver IL-5 expression 449 and with mast cell infiltration455. 
Infiltrating eosinophils are degranulating, releasing ECP, MBP, and EDN, which can also be detected in the 
serum453, 456. Some patients have autoantibodies to eosinophil peroxidase (EPX)457, although it is unclear 
whether these have any pathologic relevance. Two of the established mouse models for primary biliary 
cirrhosis show eosinophil infiltration in the liver and could be useful for further studies on the role of 
eosinophils458-460. 
Ursodeoxycholic acid (UDCA) is the only approved drug for primary biliary cirrhosis patients. UDCA can delay 
disease progression and improve liver biochemistry446. Of note, a higher frequency of blood eosinophils is 
associated with better response to UDCA treatment454. UDCA treatment decreases the frequency and 
number of eosinophils in the blood454, 461 and in the liver456 and decreases degranulation of tissue 
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eosinophils and serum MBP and EDN456. UDCA may suppress tissue eosinophilia by altering dendritic cells 
and the local cytokine milieu462. 
In some cases, eosinophilia may precede the detection of liver pathology, suggesting that eosinophils are 
involved early in the disease processes. One study reports on 4 cases of asymptomatic women with 
eosinophilia detected during random investigation. All of them had elevated liver enzymes and were 
diagnosed with primary biliary cirrhosis463. In another patient eventually diagnosed with primary biliary 
cirrhosis, eosinophilia was detected 18 months prior to diagnosis but liver enzymes were still normal 12 
months prior to diagnosis, suggesting that eosinophilia can precede overt liver pathology464. In conclusion, 
there is some evidence for a role of eosinophils in the early stages of primary biliary cirrhosis. 
Other diseases 
Several rare diseases with a possible autoimmune etiology are associated with eosinophils. Usually only 
case reports or small case series are available for these diseases making it very difficult to rule out or assign 
a pathologic or protective role to eosinophils. 
Eosinophilic cellulitis (Wells syndrome) is a very rare skin disease characterized by recurrent edematous 
erythema. Eosinophilic cellulitis is potentially associated with EGPA, HES, UC or other causes but the 
etiology is unknown465, 466. The typical histopathological sign is flame figures, the focal accumulation of 
disintegrating eosinophils and collagen fibers. Early stages are characterized by predominantly eosinophilic 
infiltration465. Blood eosinophilia is present in 15-67% of patients466. Blood eosinophils from patients with 
eosinophilic cellulitis express the high-affinity IL-2 receptor CD25467. In vitro, IL-2 treatment of CD25+ 
eosinophils resulted in priming and increased release of ECP upon subsequent platelet-activating factor 
stimulation. This suggests that eosinophils in patients with eosinophilic cellulitis may degranulate more 
easily. Indeed, extracellular MBP staining is readily observed in flame figures468, 469 and may be in amyloid 
form, a sign of large-scale degranulation470. Eosinophil chemotactic factors CCL17 and CCL24 have been 
detected in lesions471. It is possible that eosinophils play a pathogenic role through degranulation. 
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Eosinophilic fasciitis is characterized by thickening and inflammation of the fascia resulting in painful 
swelling and progressive induration of the skin and soft tissues472, 473. The etiology of eosinophilic fasciitis is 
unknown. Autoimmune disease, infections, drugs, physical exertion and other factors are discussed as 
potential triggers474. There is no clear predominance by sex. Anti-nuclear antibodies are present in 15-20% 
of patients475. Blood eosinophilia is present in most cases (60-90%) and eosinophils infiltrate the fascia and 
sometimes the perimysium476-478. This increase in eosinophils is not always present and may be a transient 
feature. In one study, blood or tissue eosinophilia were not associated with the clinical outcome (cure 
versus residual fibrosis)477.  
The fibro-inflammatory IgG4-related disease can affect multiple organs including the pancreas, salivary and 
lacrimal glands, lungs, retroperitoneum, and other tissues479, 480. While it seems to be an immune-mediated 
disease, no target antigen (autoimmune or microbial) has been identified481. The etiology and triggering 
factors are unknown480. High serum IgG4 is present in 60-70% of patients482, but it is unclear whether these 
IgG4 antibodies are directly pathogenic480, 481, 483, 484. Key histopathological features are a dense 
lymphoplasmacytic infiltrate, storiform fibrosis, and obliterative phlebitis479. Peripheral blood eosinophilia 
is found in about 30% of patients485. Eosinophils also infiltrate the tissues and are present in the majority of 
lesions. Eosinophil infiltration is usually mild to moderate but can be predominant in some cases479. To date, 
there is no clear evidence for or against a pathogenic role of eosinophils. However, several potential 
mechanisms have been hypothesized: antigen presentation, release of pro-fibrotic factors, and promotion 
of plasma cell survival for IgG4 production481. 
Autoimmune diseases in patients with eosinophil-associated diseases 
Eosinophils are a key feature of asthma, hypereosinophilic syndromes and eosinophilic gastrointestinal 
diseases. An increased frequency of autoimmune diseases in patients with these eosinophil-associated 




There are numerous case reports of patients with hypereosinophilic syndrome who also suffer from an 
autoimmune disease including ulcerative colitis, autoimmune hepatitis, autoimmune thyroiditis, multiple 
sclerosis, systemic lupus erythematosus, antiphospholipid syndrome, myasthenia gravis, and rheumatoid 
arthritis486-501. Some of these patients had more than one autoimmune disease. From these case reports, 
the overall frequency of autoimmune diseases in HES cannot be determined. It is also not clear if HES 
precedes autoimmune disease or vice versa. In a trial of mepolizumab therapy for HES, 5 out of 78 patients 
under follow-up developed autoimmune diseases (rheumatoid arthritis, polymyalgia rheumatica, temporal 
arteritis, lichen planus, autoimmune thrombocytopenia)502. These diseases were likely revealed by the 
tapering of glucocorticoids but an effect of mepolizumab cannot be excluded. It seems that these are in 
excess of the expected prevalence of autoimmune diseases, however, future studies are required to 
determine if this is the case. 
Eosinophilic gastrointestinal diseases 
Autoimmune diseases may be associated with eosinophilic gastrointestinal diseases. A recent literature 
review summarized case reports of autoimmune connective tissue diseases (SLE, rheumatoid arthritis, 
systemic sclerosis, and inflammatory myositis) in patients with eosinophilic gastroenteritis503. These 
patients were mostly female even though eosinophilic gastroenteritis shows a male predominance. The 
issue remains that case reports don’t allow for any conclusion of association. A recent population based 
cohort study on eosinophilic esophagitis found that the risk of several autoimmune diseases was 
substantially increased in patients compared to controls504. Eosinophilic esophagitis patients had an 
increased risk of celiac disease, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, lupus, systemic 
sclerosis, Hashimoto’s thyroiditis, and multiple sclerosis. No increased risk was found for pernicious anemia 
or vitiligo. Whether female compared to male eosinophilic esophagitis patients were more likely to also 
suffer from an autoimmune disease was not assessed. Genome-wide association studies have identified 
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risk loci for eosinophilic esophagitis that were previously associated with autoimmune diseases, suggesting 
a potential common genetic cause505. It will be interesting to see if eosinophilic esophagitis patients with 
autoimmune comorbidities differ from those without and whether an association of other eosinophilic 
gastrointestinal diseases with autoimmune diseases can be proven. 
Asthma 
Eosinophils are a prominent feature of allergic asthma and, to a lesser extent, of non-allergic asthma506. A 
potential role for autoimmune processes in asthma has been proposed507. Patients with asthma carry 
autoantibodies more often than healthy controls508, 509 and some studies have found a positive association 
of asthma with autoimmune diseases510-512. However, others report negative associations between these 
two conditions513, 514. It has also been suggested that sex hormones may contribute to asthma severity515. 
Non-allergic asthma has a female predominance, while allergic asthma does not516, 517. Whether 
autoimmunity plays a role in asthma pathology or is increased in affected individuals remains controversial. 
To date, there is limited evidence for increased autoimmune diseases in patients with HES, asthma or 
eosinophilic gastrointestinal disease and only one study that determined an increased risk in EoE patients. 
Future cross-sectional or cohort studies will be required to determine if the prevalence of autoimmune 
diseases is truly higher in patients with eosinophil-associated diseases. 
Conclusions 
There is clear evidence for a pathogenic role of eosinophils in several autoimmune diseases. Protective 
functions of eosinophils have not been identified. Eosinophils contribute to autoimmune diseases in vastly 
different organs, from the central nervous system to the skin, gastrointestinal tract, and cardiovascular 
system. These include tissues where eosinophils reside in healthy individuals, such as the intestine, as well 
as those where eosinophil are usually absent, such as the heart or central nervous system. In all of these 
organs, eotaxins seem to be the main chemokines for eosinophil recruitment. Different eotaxins attract 
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eosinophils to different tissues. Eotaxin-1 is essential for eosinophil trafficking to the intestine, while 
eotaxin-3 is most important in EGPA. Both eotaxin-1 and -3 attract eosinophils to the heart and eotaxin-2 
and -3 recruit eosinophils to the central nervous system in NMO. Eosinophil infiltration into tissues is usually 
accompanied by eosinophilia, which may be transient, and is often caused by an increase in serum IL-5 or 
tissue IL-5. Other cytokines like GM-CSF may also be increased and contribute to eosinophilia. Compared 
to healthy controls, eosinophils from affected tissues or blood of patients show an activated phenotype, 
upregulating CD11b and CD69, and releasing cytokines such as IL-25, IL-6, IL-8, and IL-1β.  
Multiple effector mechanisms have been identified (Figure 32). Degranulation of eosinophils is noted most 
frequently, perhaps because it is easily visualized by immunofluorescence or histology of biopsies. 
Degranulating eosinophils are often seen adjacent to dying cells, such as endothelial cells of the vasculature 
and endocard, nerve cells, dermis, and intestinal mucosa. As a result, direct cytotoxicity of eosinophils to 
other cells has been proposed as a mechanism in all autoimmune diseases discussed above. EPX, MBP and 
ECP all have strong cytotoxic properties and often multiple mediators are released. The ability of eosinophils 
to bind antibodies and subsequently degranulate and kill cells links the adaptive autoimmune response to 
eosinophil effector functions. Antibody-dependent cell mediated cytotoxicity by eosinophils was shown for 
NMO. Antibodies in BP likely cause degranulation of eosinophils and blister formation. Eosinophils are 
frequently associated with tissue remodeling. In BP, eosinophil-derived MMP9 and neutrophil elastase were 
shown to degrade extracellular matrix proteins resulting in dermal-epidermal separation. In ulcerative 
colitis, MBP and corticotrophin-releasing factor from eosinophils downregulate tight-junction proteins on 
epithelial cells, which decreases their barrier function. Eosinophil-derived cytokines modulating the 
function of other immune or stromal cells also play a role in autoimmune diseases. Eosinophil-derived IL-4 
is important for chronic disease progression in myocarditis and IL-22BP blocks protective functions of IL-22 
in UC. In several diseases, eosinophil infiltration was particularly pronounced in the early stages. This may 
hint to a role in initiation of the autoimmune response, a hypothesis that is difficult to prove in humans. 
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Particularly for rare diseases, the evidence for eosinophil involvement is mostly based on case reports, 
which makes it difficult to exclude associations by chance. Because autoimmune disease patients may 
receive many drugs, it is worth considering that hypersensitivity reactions to drugs are often accompanied 
by eosinophilia. On the other hand, it is difficult to ascertain the role of eosinophils in patients treated with 
glucocorticoids, which are highly effective at reducing eosinophil numbers in blood and organs518, 519. 
Eosinophils may be reduced to normal or below normal levels in patients under treatment, and this could 
mask any associations. Novel targeted therapeutics that affect only specific arms of the immune response 
and don’t dampen eosinophils may reveal new associations.  
Future research needs 
To verify some of the proposed mechanisms and potentially identify new mechanisms of eosinophil-
mediated pathology or protection in autoimmune disease, animal models will aid greatly. The lack of in 
vitro or animal models has hampered research in several autoimmune diseases such as EGPA and primary 
biliary cirrhosis. In addition, epidemiological studies including larger patient cohorts will be required to 
determine whether autoimmune diseases are indeed increased in patients with eosinophil-associated 
diseases such as eosinophilic esophagitis, hypereosinophilic syndrome, or asthma. Lastly, viewing and 
analyzing autoimmune diseases with eosinophil-involvement as a group with possible shared mechanisms 








Figure 32: Possible mechanisms of eosinophil-mediated damage in autoimmune diseases  
In neuromyelitis optica, eosinophils damage astrocytes through antibody-dependent and complement-
dependent cell mediated cytotoxicity. Eosinophil degranulation in damaged bile ducts was shown for 
primary biliary cirrhosis. In bullous pemphigoid, eosinophils release proteases that degrade the dermal-
epidermal anchoring complex. Eosinophil infiltration in the heart results in damage to the endocard and 
myocard either directly or indirectly through mast cells. Eosinophil-derived IL-4 can drive progression from 
autoimmune myocarditis to dilated cardiomyopathy. In inflammatory bowel diseases, eosinophils can 
damage the mucosa through multiple mechanisms. Eosinophil granule proteins damage epithelial cells and 
increase epithelial barrier permeability. Eosinophil-derived IL-22BP blocks the protective effects of IL-22 on 
epithelial cells. GM-CSF may prolong survival and activation of eosinophils in the intestine. In EGPA, 
eosinophils damage nerves and blood vessels. Abbreviations: CNS, central nervous system; AQP4, 
aquaporin 4; FcR, Fc-receptor; BP-180, bullous pemphigoid 180; RBC, red blood cell; DCM, dilated 
cardiomyopathy; EPX, eosinophil peroxidase; CRH, corticotropin-releasing hormone; MBP, major basic 
protein; IL-22BP, IL-22 binding protein; GM-CSF, granulocyte-macrophage colony stimulating factor; Th17, 
T-helper 17 cell; Th2, T-helper 2 cell.  
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Chapter 6: Conclusions and future directions 
We established a clear role for eotaxins and the eotaxin receptor CCR3 in eosinophil trafficking to the heart 
in a mouse model of eosinophilic myocarditis74. We identified the cellular source of eotaxin-1 as cardiac 
fibroblasts with interstitial localization in the heart and of eotaxin-2 as F4/80+ macrophages localized at 
inflammatory foci. Expression of these chemokines is controlled by the Th2 cytokines IL-4 and IL-13. 
Furthermore, we demonstrated that eotaxins are also increased in patients with eosinophilic myocarditis 
and expression levels of eotaxin-1 and -3 are positively correlated with the number of heart infiltrating 
eosinophils. These results demonstrate that eosinophil trafficking to the heart is dependent on the eotaxin-
CCR3 pathway in a mouse model and associated with eotaxin expression in patients with eosinophilic 
myocarditis. Our findings suggest that it might be possible to prevent eosinophil trafficking to the heart by 
blocking eotaxins. Monoclonal antibodies against eotaxin-1 are currently being evaluated in clinical trials 
(ClinicalTrials.gov identifiers: NCT01671956, NCT02226146). 
Several questions remain open. We have not identified the cellular source of eotaxins in humans. It would 
be interesting to see whether the same cell types that express eotaxins in mice also produce eotaxins in 
humans. Moreover, our studies were done on a relatively small number of patients (16 with eosinophilic 
myocarditis and 14 with chronic lymphocytic myocarditis) and should be repeated with a larger cohort of 
patients and with additional groups of patients. For example, it would be of interest to see whether patients 
with giant cell myocarditis, who often have substantial cardiac eosinophil infiltration as well, also have 
increased expression of eotaxins.  
Eotaxins are not the only chemokines that attract eosinophils. A limitation of our investigations is that we 
did not evaluate the expression of other chemokines like CCL5 or leukotrienes in eosinophilic myocarditis 
patients. The expression levels of these different chemokines should be analyzed and compared and their 
correlation to eosinophil infiltration should be assessed. These experiments would give insight into the 
importance of eotaxins and other chemokines for eosinophil trafficking to the heart. There are 2 eotaxins 
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in mice and 3 eotaxins in humans. We did not evaluate the relative importance of these chemokines. Others 
have shown that eotaxin-1 is important for eosinophil trafficking to the intestine69 and eotaxin-2 for 
eosinophil trafficking to the lungs in allergic asthma models72. The relative importance of eotaxin-1 and -2 
in experimental eosinophilic myocarditis could be tested by blocking each and both cytokines with 
monoclonal antibodies. More important, yet much more difficult to address, would be to understand which 
eotaxins regulate eosinophil trafficking to the heart in humans. Our studies showed tremendous increase 
in eotaxin-1 and -3 in eosinophilic myocarditis patients. It is possible that blocking only one of these 
chemokines will not be sufficient to prevent eosinophil trafficking. This might set trials of the anti-eotaxin-
1 antibodies currently in development up for failure. Antibodies against other eotaxins are not in clinical 
trials at this time. 
Another intriguing question is whether there is a difference between patients with and without peripheral 
blood eosinophilia. Our model of eosinophilic myocarditis in IFNγ-/-IL-17A-/- mice has normal peripheral 
blood eosinophil numbers while that in IL-5Tg mice has hypereosinophilia. Eosinophil infiltration reaches 
over 60-80% in IL-5Tg mice but only 30% in IFNγ-/-IL-17A-/- mice, yet eotaxins are dramatically increased 
(100-fold) in the hearts of IFNγ-/-IL-17A-/- mice but only minimally (2-8-fold in the atria) in IL-5Tg mice. This 
leads to the hypothesis that high cardiac eotaxin expression is required for eosinophilic myocarditis in 
individuals with normal blood eosinophil numbers but not in those with hypereosinophilia. This hypothesis 
should be tested in patients as it may define the patient population for which eotaxin blockade may be 
useful.  
Of course, the question remains whether the presence of eosinophils in the heart in patients with 
eosinophilic myocarditis actually contributes to pathology. While this is widely assumed it cannot easily be 
proven. New therapeutics such as anti-IL-5 and anti-IL-5 receptor antibodies are now being employed in 
eosinophil-associated conditions and offer a rare opportunity to assess the function of eosinophils in 
patients in vivo520. Anti-IL-5 antibodies substantially diminish eosinophil numbers by blocking 
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eosinophilopoiesis in the bone marrow. Anti-IL-5 receptor antibodies deplete eosinophils and other cell 
types expressing this surface receptor and can reduce eosinophils to undetectable levels in patients. These 
novel drugs have not yet been employed in patients with any form of eosinophilic myocarditis, but may 
reveal the function of this cell type once they are utilized.  
In a different set of experiments, we sought to determine the role of eosinophils in myocarditis and its 
progression to DCM. Eosinophils were dispensable for myocarditis induction but required for progression 
to DCMi. Eosinophil-deficient ΔdblGATA1 mice, in contrast to WT mice, showed no signs of heart failure by 
echocardiography. Induction of EAM in hypereosinophilic IL-5Tg mice resulted in eosinophilic myocarditis 
with severe atrial inflammation, which progressed to severe DCMi. This was not a direct effect of IL-5 as IL-
5TgΔdblGATA1 mice were protected from DCMi while IL-5-/- mice exhibited DCMi comparable to WT mice. 
A caveat regarding the phenotype of the IL-5-/- mice is that the eosinophil numbers in the heart during EAM 
were not established. Nevertheless, we conclude from these results that eosinophils are dispensable for 
myocarditis initiation, drive progression of myocarditis to DCMi and cause severe myocarditis and DCMi 
when present in large numbers. These findings demonstrate clearly a pathogenic role for eosinophils in 
myocarditis.  
There are some limitations of the IL-5Tg mouse model in that it does not recapitulate the exact pathology 
that is seen in patients with HES (outlined in the discussion of Chapter 4). Clearly there are large difference 
between mouse models and the pathophysiology in patients. An additional reason for the different 
histopathology may be the induction of disease in IL-5Tg mice. We used the EAM model which causes an 
autoimmune response against cardiac muscle. As expected, the IL-5Tg mice developed myocarditis. In 
humans, it is not clear what initiates the endomyocardial damage as some patients with HES develop these 
features while others live with hypereosinophilia but without cardiac manifestations for many years35. We 
are currently examining a cohort of IL-5Tg mice for the development of spontaneous cardiac disease. In 
these mice, we will determine pathological changes by echocardiography, electrocardiogram and histology 
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in comparison to age- and sex-matched WT littermates. It is possible that the spontaneous disease 
developing in IL-5Tg mice may replicate more features of cardiac pathology seen in HES patients. We have 
also done a microarray on cardiac tissues from IL-5Tg, WT and ΔdblGATA1 mice and are currently analyzing 
the data. Even in naïve mice, there is a dramatic pro-inflammatory signature in IL-5Tg mice compared to 
the other two groups. Further analysis may reveal interesting processes resulting from the presence of large 
numbers of eosinophils in the heart. 
We also identified the mechanism by which eosinophils promoted DCMi. Our experiments showed that 
eosinophils were the major IL-4 expressing cell type in the heart during EAM, IL-4-/- mice were protected 
from DCMi like ΔdblGATA1 mice, and eosinophil-specific IL-4 deletion resulted in improved heart function. 
Thus, eosinophils drove progression to DCMi through their production of IL-4. These findings naturally lead 
to the question of what role IL-4 plays in human myocarditis. Little is known in this field and future studies 
should look into the expression of IL-4 in myocarditis and DCM patients to determine whether there is a 
correlation with disease progression. It would also be interesting to know whether patients with 
eosinophilic myocarditis have higher IL-4 expression compared to patients with lymphocytic or other types 
of myocarditis. 
Our results did not rule out the possibility of additional eosinophil effector mechanisms in myocarditis and 
DCM. Eosinophil-specific IL-4 deletion resulted in a significant increase in ejection fraction compared to WT 
mice, but the difference was smaller than between WT and ΔdblGATA1 or WT and IL-4-/- mice. There are 
two possible explanations for these results: incomplete deletion of IL-4 in eosinophils or additional 
mechanisms by which eosinophils promote DCM. We showed that the recombination in EoCrewt/tg mice is 
not complete by crossing these mice to the delete strain ROSA-DTA. Eosinophils were significantly reduced, 
but not completely absent. However, the possibility of other eosinophil-derived effectors that promote 
DCM cannot be ruled out. 
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Future experiments will focus on the function of IL-4 in DCM. The main questions that need to be addressed 
are: What are the target cells of IL-4? What effect does IL-4 have on these cells? How does that promote 
the development of DCM? We already know that IL-4 induces eotaxin expression in cardiac fibroblasts and 
macrophages. This suggests a possible feed-forward loop in which eosinophil-derived IL-4 promotes local 
eotaxin expression which in turn recruits more eosinophils into the heart. The effect of IL-4 on fibroblasts 
and macrophages is probably not limited to eotaxin production. Other target cells of IL-4 could be 
endothelial cells, which have been shown to respond with increasing vascular permeability and 
upregulation of cell adhesion molecules. Other immune cells in the lymphoid and myeloid lineages can also 
respond to IL-4. To address the question of target cells, IL-4Rα1 expression can be analyzed by flow 
cytometry as a first step. Once potential target cells are identified, the next step is to delete the receptor 
on specific cell types. For this, we have already acquired IL-4Rα1 floxed mice that can be crossed to mice 
expressing cell-specific Cre recombinase. The downstream effects of IL-4 and the link to the development 
of DCM remain entirely elusive at this point and may form the intriguing project of a future student.  
By reviewing the role of eosinophils in other autoimmune diseases, we identified potential common 
effector mechanisms. We also found that eotaxins seem to play a key role in eosinophil localization to 
organs in all the disease where they were studied. Eosinophils may play an underappreciated role in certain 
autoimmune diseases and it may advance our understanding to compare and contrast these conditions. 
The development of new eosinophil-targeted drugs will offer exciting insights into the role of eosinophils in 
human disease and help answer some decades-old questions on the function of eosinophils in allergic 
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